EP3946281A1 - Polymer films comprising material secreted by gastropods - Google Patents
Polymer films comprising material secreted by gastropodsInfo
- Publication number
- EP3946281A1 EP3946281A1 EP20714636.6A EP20714636A EP3946281A1 EP 3946281 A1 EP3946281 A1 EP 3946281A1 EP 20714636 A EP20714636 A EP 20714636A EP 3946281 A1 EP3946281 A1 EP 3946281A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- film
- films
- solution
- polymer
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000237858 Gastropoda Species 0.000 title claims abstract description 243
- 239000000463 material Substances 0.000 title claims abstract description 131
- 229920006254 polymer film Polymers 0.000 title description 3
- 229920000642 polymer Polymers 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 73
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- 235000013305 food Nutrition 0.000 claims abstract description 32
- 239000002537 cosmetic Substances 0.000 claims abstract description 28
- 238000004806 packaging method and process Methods 0.000 claims abstract description 16
- 229920001661 Chitosan Polymers 0.000 claims description 168
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 93
- 229920000159 gelatin Polymers 0.000 claims description 93
- 235000019322 gelatine Nutrition 0.000 claims description 93
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 92
- 239000001828 Gelatine Substances 0.000 claims description 78
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 50
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 49
- 229920002678 cellulose Polymers 0.000 claims description 39
- 239000001913 cellulose Substances 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 29
- 235000014655 lactic acid Nutrition 0.000 claims description 25
- 239000004310 lactic acid Substances 0.000 claims description 25
- 229960004106 citric acid Drugs 0.000 claims description 23
- 235000015165 citric acid Nutrition 0.000 claims description 23
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 18
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical group C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 18
- 229960004884 fluconazole Drugs 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 238000001704 evaporation Methods 0.000 claims description 16
- 229920003023 plastic Polymers 0.000 claims description 16
- 239000004033 plastic Substances 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 239000011888 foil Substances 0.000 claims description 14
- 210000003097 mucus Anatomy 0.000 claims description 14
- 229940121375 antifungal agent Drugs 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 210000004877 mucosa Anatomy 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000003429 antifungal agent Substances 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 238000012377 drug delivery Methods 0.000 claims description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 206010052428 Wound Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 208000035484 Cellulite Diseases 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010049752 Peau d'orange Diseases 0.000 claims description 6
- 238000002441 X-ray diffraction Methods 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 5
- 208000031439 Striae Distensae Diseases 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 230000036232 cellulite Effects 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 206010040872 skin infection Diseases 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 4
- 206010061304 Nail infection Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229920001971 elastomer Polymers 0.000 claims description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 4
- 229940114124 ferulic acid Drugs 0.000 claims description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 4
- 235000001785 ferulic acid Nutrition 0.000 claims description 4
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- 229940074391 gallic acid Drugs 0.000 claims description 4
- 239000005060 rubber Substances 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 4
- 238000002834 transmittance Methods 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 206010063409 Acarodermatitis Diseases 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 229910016523 CuKa Inorganic materials 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 3
- 208000010195 Onychomycosis Diseases 0.000 claims description 3
- 206010057342 Onychophagia Diseases 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 206010046914 Vaginal infection Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000003904 antiprotozoal agent Substances 0.000 claims description 3
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 239000004927 clay Substances 0.000 claims description 3
- 229910052570 clay Inorganic materials 0.000 claims description 3
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 239000003410 keratolytic agent Substances 0.000 claims description 3
- 239000010445 mica Substances 0.000 claims description 3
- 229910052618 mica group Inorganic materials 0.000 claims description 3
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 208000005687 scabies Diseases 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 201000005882 tinea unguium Diseases 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims description 2
- 239000001263 FEMA 3042 Substances 0.000 claims description 2
- 208000004898 Herpes Labialis Diseases 0.000 claims description 2
- 206010065755 Lip infection Diseases 0.000 claims description 2
- 206010065764 Mucosal infection Diseases 0.000 claims description 2
- 206010067152 Oral herpes Diseases 0.000 claims description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 206010053615 Thermal burn Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010048038 Wound infection Diseases 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 229940124326 anaesthetic agent Drugs 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 201000005884 exanthem Diseases 0.000 claims description 2
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- 229920002258 tannic acid Polymers 0.000 claims description 2
- 235000015523 tannic acid Nutrition 0.000 claims description 2
- 229940033123 tannic acid Drugs 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 10
- 239000000243 solution Substances 0.000 description 204
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 120
- 239000000203 mixture Substances 0.000 description 110
- 238000003756 stirring Methods 0.000 description 78
- 210000003491 skin Anatomy 0.000 description 58
- 239000001768 carboxy methyl cellulose Substances 0.000 description 47
- 239000004698 Polyethylene Substances 0.000 description 45
- 229940014041 hyaluronate Drugs 0.000 description 42
- 230000035882 stress Effects 0.000 description 42
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 39
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 38
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 33
- 239000008279 sol Substances 0.000 description 28
- 238000005063 solubilization Methods 0.000 description 24
- 230000007928 solubilization Effects 0.000 description 24
- 230000000844 anti-bacterial effect Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 23
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 23
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 23
- 230000001070 adhesive effect Effects 0.000 description 22
- 229940079593 drug Drugs 0.000 description 22
- 238000000935 solvent evaporation Methods 0.000 description 22
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 21
- 241000283690 Bos taurus Species 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 20
- 239000008213 purified water Substances 0.000 description 19
- 230000008961 swelling Effects 0.000 description 19
- 229940072056 alginate Drugs 0.000 description 18
- 235000010443 alginic acid Nutrition 0.000 description 18
- 229920000615 alginic acid Polymers 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 18
- 239000000853 adhesive Substances 0.000 description 17
- 239000000306 component Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 16
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 230000035699 permeability Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 241000282898 Sus scrofa Species 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 14
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 14
- 108010010803 Gelatin Proteins 0.000 description 14
- -1 extensible Substances 0.000 description 14
- 229940126864 fibroblast growth factor Drugs 0.000 description 14
- 239000008273 gelatin Substances 0.000 description 14
- 235000011852 gelatine desserts Nutrition 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000004132 cross linking Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 12
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 11
- 241000237367 Helix aspersa Species 0.000 description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 11
- 238000009792 diffusion process Methods 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 229940010747 sodium hyaluronate Drugs 0.000 description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 235000010413 sodium alginate Nutrition 0.000 description 9
- 239000000661 sodium alginate Substances 0.000 description 9
- 229940005550 sodium alginate Drugs 0.000 description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
- 229920003091 Methocel™ Polymers 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000004014 plasticizer Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 238000009864 tensile test Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 241000237369 Helix pomatia Species 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000000227 bioadhesive Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 230000020477 pH reduction Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 241001441828 Helix lucorum Species 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000237852 Mollusca Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001887 cortisones Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229960003913 econazole Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 238000000807 solvent casting Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000003813 thumb Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 244000197813 Camelina sativa Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000222173 Candida parapsilosis Species 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 241001298368 Cantareus apertus Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241001299994 Cernuella virgata Species 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241001301244 Euglandina rosea Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241001071795 Gentiana Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000202102 Helix albescens Species 0.000 description 2
- 241000250597 Helix godetiana Species 0.000 description 2
- 241000202119 Helix lutescens Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001552465 Massylaea vermiculata Species 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- IABBAGAOMDWOCW-UHFFFAOYSA-N Nicametate citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)CCOC(=O)C1=CC=CN=C1 IABBAGAOMDWOCW-UHFFFAOYSA-N 0.000 description 2
- 241000286899 Otala lactea Species 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 238000012356 Product development Methods 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 241001300045 Theba pisana Species 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 241001183823 Tyrrhenaria ceratina Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 2
- 229960001610 denatonium benzoate Drugs 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 210000005224 forefinger Anatomy 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 108010025899 gelatin film Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229940096857 opUNTia ficus-indica extract Drugs 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 2
- 229960000490 permethrin Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 229960003600 silver sulfadiazine Drugs 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 235000019654 spicy taste Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229940025703 topical product Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical group C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000237364 Achatina fulica Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241001458848 Arion subfuscus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 241000237365 Helicidae Species 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 241001523405 Limax Species 0.000 description 1
- 240000008964 Livistona australis Species 0.000 description 1
- 241001353886 Macrochlamys indica Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Norphytane Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000543567 Rapana venosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000012996 alamarblue reagent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021452 apple slice Nutrition 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 239000008214 highly purified water Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Inorganic materials [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940066974 medicated patch Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 238000000175 multiple-ion monitoring Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Definitions
- the present invention refers to a film, comprising at least one polymer and a material secreted by a gastropod, in particular snail slime.
- the present invention also relates to a procedure for the preparation and to uses of such film, in particular medical and cosmetic uses, including veterinary uses. Further objects of the present invention include kits, films for the storage and/or packaging of food, patches, masks and similar cosmetic products comprising such film.
- the material secreted by snails includes numerous substances such as mucopolysaccharides, collagen, elastin, allantoin, glycolic acid, lactic acid, proteins, vitamins (vitamin A, E, C, B1 and B2), free amino acids, peptides, enzymes and trace minerals. Thanks to its characteristic composition, snail slime is known for its numerous advantageous properties, such as: cicatrizing, antibacterial, hydro-restorative, moisturizing, soothing, nourishing, regenerating, anti-wrinkle, anti-stretch mark, anti-acne, anti-stain. It is also capable of improving the appearance of scars and blemishes of various kinds (e.g. cellulite and stretch marks). In addition, the adhesive (J.
- snail slime products include:“Maschera Viso BIO con Acido Ialuronico e Aloe Vera” by Helidermina (http://www.helidermina.com/) and“Snail Jelly Mask” by SKEDERM (http://skederm.com/product/skederm-snail-jelly- mask-10-sheets-hydrogel-coated- facial-mask-with-snail-secretion-filtrate-5000ppm/).
- US patent 5,538,740 discloses an active ingredient extracted from snail useful for the therapeutic and cosmetic treatment of skin and mucosa, as well as creams comprising the same.
- Patent applications US 2017/0281690 A1 and US 2017/0216368 A1 describe the use of snail slime in liquid formulation in the treatment of rosacea and psoriasis, while patent application US 2013/0309296 A1 describes a device (gauze type) based on snail slime, for the prevention and treatment of diabetic ulcers and burns.
- Patent application US 2010/0233111 A1 relates to cosmetic and pharmaceutical formulations comprising a biological fluid collected from gastropods (including in particular Helix Aspersa Muller) and methods for their preparation/production. They are useful for skin care. Such document further describes a method of collecting and refining biological fluid from gastropods. However, such document does not relate to compositions in the form of a film.
- Patent application WO 2016/069396 A2 discloses a polymer film suitable for use as a face mask or transdermal patch, containing at least 30 wt. % of a thermoplastic polyurethane polymer and up to 5 wt. % of water.
- Such a film optionally comprises an active agent, which may be, among others, an agent that stimulates or regulates keratinocyte differentiation.
- an agent that stimulates or regulate keratinocyte differentiation are the gly coconjugates of Helix Aspersa Muller.
- J. Li et al. (J. Li et ah, Science , 2017, 357, 378-381) developed resistant adhesives (“Tough Adhesives”, TAs) composed of two layers.
- the first layer is an adhesive surface comprising a positively interpenetrated polymer, while the second layer is a hydrogel- based dissipative matrix.
- A. S. Haiti et al. (A. S. Haiti et al., Int. ./. Pharma Med. Biol. Sci., 2016, 5, 1, 76-80) report that administration of snail slime and chitosan is effective in wound healing.
- a product comprising a material secreted by a gastropod that is adhesive and exhibits mechanical properties (e.g. elasticity and plasticity) useful for applying the product on skin, mucous membranes and/or nails.
- the present invention relates to the addition of a material secreted by a gastropod, particularly snail slime, in liquid or lyophilised form, to formulations in the form of a film.
- a material secreted by a gastropod particularly snail slime
- the presence of the material secreted by a gastropod, preferably snail slime allows to obtain films with unexpected properties, such as high flexibility, elasticity and bioadhesiveness.
- the films of the invention possess considerable advantages for applications in the cosmetic, pharmaceutical and veterinary fields as detailed below.
- the films can be loaded with active molecules.
- films loaded with an antifungal agent fluconazole
- KB Kirby-Bauer
- the authors have developed films based on polymers, in particular natural, semisynthetic and/or biodegradable polymers, comprising a material secreted by a gastropod, preferably snail slime, in various concentrations for cosmetic, pharmaceutical and veterinary applications.
- the authors focused on the development of the formulation and on the preparation of such films. They may be prepared by solvent casting and may comprise further agents, in particular excipients, cosmetic agents and/or therapeutic agents.
- the films according to the present invention are characterized by numerous advantageous properties. For example, tensile tests revealed that they are endowed with desirable mechanical properties, such as high extensibility, stretchability, flexibility, deformability and manageability and at the same time reduced/low stiffness, rigidity and fragility. In addition, such films exhibit both elastic and plastic properties. At the same time, the films exhibit a bioadhesive behaviour, without requiring the addition of an adhesive agent.
- the obtained films are bioadhesive, extensible, plastic, flexible.
- the addition of adhesive polymers may be unnecessary depending on the type of formulation.
- the films of the present invention are neither rigid nor fragile. Therefore, they can be easily elongated and/or subjected to multiple stresses without breaking and exerting a light force. This makes them extremely versatile and adaptable.
- the films of the invention have proved effective at adhering to the surface of application, e.g. skin, nails, mucosa (e.g. gingival) and lips for prolonged periods of time (e.g. multiple hours), even when applied to areas subjected to frequent movement (e.g. palm of the hand, groove of arm).
- films of the invention may have a transparency value measured as described below lower than 5 and a T% measured as described below equal to zero at 200-280 nm, suggesting that they may be used as sunscreen, e.g. to store food.
- the films of the invention are characterised by a low water vapour permeability. It has also been found that film solubility and swelling degree and water vapour permeability may be controlled by changing film composition, so that films may be tailored to the intended use and a broad field of use can be covered. For instance, the films of the invention may act as fast dissolving films.
- the solubility of the films in water varies from complete solubility in a few minutes to insolubility for several months.
- Thickness of the films may also be tailored to the specific need.
- films of the invention have a thickness from 30 pm to 350 pm or from 50 pm to 350 pm. Variations in composition can be utilized to modulate the properties of the films for possible applications including those for the biomedical field or as edible coating for food packaging.
- films of the invention do not interfere with cell proliferation or cell viability. Moreover, they do not cause Lactate Dehydrogenase (LDH) release, which indicates that they are not cytotoxic. Overall, films of the invention possess a promising safety profile. Additionally, they stimulate Fibroblast Growth Factor (FGF) and Collagen type 1 (COL1) release/production, i.e. in treated fibroblasts, there is a higher level/amount of FGF and COL1 than in untreated fibroblasts.
- FGF Fibroblast Growth Factor
- COL1 Collagen type 1
- a material secreted by a gastropod confers to the films the properties of such material, such as for example cicatrizing, antibacterial, moisturizing, soothing, nourishing, regenerating, anti-wrinkle, anti-cellulite, anti-stretch marks, anti-acne, anti stain, improving the appearance of scars and blemishes of various kinds.
- the material acts like a plasticizer enhancing films extensibility and strongly improving their water barrier and bioadhesion properties, with a trend depending on material’s content.
- the material provides the films with antibacterial properties and enhanced cytocompatibility, yielding materials with tailored properties for specific requirements.
- the films of the invention have also proved effective at reducing the spread of a variety of Gram-negative and Gram-positive bacteria.
- films of the invention particularly suitable for application to the human or animal body, in particular to the skin, mucous membranes, gums and nails.
- Films of the invention can advantageously be applied to areas of the body most susceptible to movement/bending, such as for example fingers, hands, wrists, ulnar cable, popliteal cable, ankle, armpit, feet.
- the presence of snail slime in the films provides the polymeric materials that are commonly used in the preparation of films high elastic and plastic properties (plasticizing effect), as well as a high adhesiveness (bioadhesive).
- the films object of the invention can remain adhered to the skin for more than 8 hours without the need to add adhesive polymers and can be easily removed by washing with water.
- the films produced can be applied by placing them in contact with a minimum amount of water to promote adhesiveness (non patch patch concept).
- appropriately formulated films could be used simply by wetting the skin with water and dissolving the film directly onto the skin. In this way a gelatinous film is formed as if it were a semi-solid formulation for skin application with moisturising (cosmetic) action.
- the films can be prepared as a monolayer or multilayer (one-layer or multiple layers) with varying thickness depending on the application and can be loaded with a single drug or a combination of drugs.
- the various layers could comprise different polymers depending on the application and type of active molecules inserted.
- the films of the invention may be formulated as a composition in which two or more layers of different composition are assembled, thus obtained from films consisting of different polymers so as to modulate the release properties of the inserted active substances.
- the purpose is for instance to release the active ingredient locally (skin, oral/vaginal cavity, nails).
- the films are perfectly transparent and adaptable to any shape of the body without the need to add plasticizers (additives commonly used in the formulation of films) and preservatives (bactericides and/or bacteriostats).
- a material secreted by a gastropod in particular snail slime
- a gastropod in particular snail slime
- dry lyophilised or freeze-dried
- preserving bioactivity increasing preservability over time and facilitating the storage of said material.
- Lyophilization of said material can be accomplished by a standard procedure, for example using cryoprotectants such as dextran.
- cryoprotectants such as dextran.
- the material’s bioactivity can be preserved over time by freeze-drying it.
- the polymers may be used at different % w/V according to their molecular weight.
- the films object of the present invention represent a very versatile innovative system thanks to the mechanical, chemical -physical and functional properties linked to the presence of a material secreted by a gastropod, in particular snail slime, thus useful in the pharmaceutical, veterinary and cosmetic fields.
- the following applications can be identified: moisturizing, soothing, cellulite treatment (for example with possible addition of caffeine), such as anti-wrinkle or stain remover, thanks to the exfoliating properties of secretion and for the treatment of onychophagia following the addition of substances with an unpleasant taste (currently there are enamels/solutions containing molecules such as denatonium benzoate, or plant extracts with a strong bitter and spicy taste such as gentian or rhubarb).
- the films can be drug delivery systems for both skin and mucosal application.
- the produced films represent suitable systems for the treatment of aphthas (for which aloe-based gels, mouthwashes, sprays and patches are now used), vaginal and buccal infections for the local release of antibacterials, antifungals, antiprotozoal s and antivirals.
- films loaded with appropriate medication can be used for the treatment of skin wounds (wound healing) and skin infections.
- appropriate medication anaesthetic, antiseptic, antibacterial, etc.
- the films of the invention in particular when suitably formulated with snail slime and biopolymers, can be used as food wrapper/packaging or to separate food components and also to improve the quality of food products thanks to the antibacterial activity of the films themselves.
- a film comprising at least one polymer and a material secreted by a gastropod, wherein said material is slime, mucus, or gastropod extract, and wherein said material is fresh or lyophilised.
- the film is solid and/or lacks a backing sheet and/or exhibits both elastic and plastic properties.
- Elastic and plastic properties may be measured by any method known in the art to assess them.
- elastic and plastic properties may be evaluated by stress-strain curves, in turn obtainable for example from tensile tests (e.g. constant speed tensile test) which may be performed as described in Example 14 below.
- the film exhibits elastic properties when, in the elastic part of the respective stress-strain curve, stress and strain are proportional and once the load is removed, the film recovers its original shape.
- the film exhibits plastic properties when it does not recover its original shape when the load is removed.
- the films improve their elastic properties when the amount of snail slime is high: see for example Figure 4 A II, stress strain curve referred to CS 3070 L where the material maintains its elastic properties until it breaks (over 50% of deformation).
- Films containing low snail slime content see for example Figure 4 A II, stress strain curve referred to CS 7030), show both elastic and plastic properties: the elastic region is limited to strain values less than 5%, after which the deformation mode is plastic (films do not recover their original length even if the load is removed).
- the applied solid film can act as a fast dissolving film, a mucoadhesive film and as an adhesive soluble or insoluble film.
- said polymer is natural, semi synthetic, synthetic and/or biodegradable.
- said polymer is selected from the group consisting of: gelatine, chitosan, cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, an alginate salt, carboxyvinyl polymer, rubber, carrageenan, a hyaluronate salt, starch, keratin, acrylic polymer and a combination thereof.
- said gelatine is porcine gelatine, bovine gelatine or fish gelatine.
- said cellulose is selected from the group consisting of: hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose.
- said alginate salt is sodium alginate.
- said rubber is xanthan, guar or arabic rubber.
- said acrylic polymer is a polyacrylic acid or a methylmethacrylate.
- said combination is a combination of a cellulose and a hyaluronate salt.
- said polymer is cross-linked.
- said polymer is cross-linked with an agent that is of natural origin and non-toxic.
- said polymer is cross- linked with any one of: the material secreted by a gastropod, a hyaluronate salt, a further polymer with opposite charge to said polymer, citric acid, gallic acid, tannic acid or ferulic acid. It is to be understood that cross-linking of the polymer directly with the material secreted by a gastropod takes place depending on the polymer type and/or the ratio between the polymer and the material secreted by a gastropod.
- the invention provides a film as defined above wherein said polymer is gelatine, chitosan, cellulose, an alginate salt or a hyaluronate salt and is cross-linked with an agent that is of natural origin and non-toxic, preferably with a hyaluronate salt, citric acid, gallic acid or ferulic acid.
- said polymer is cross-linked without using a cross-linking agent. For example, using 2% w/V chitosan, solubilized in 2% v/v acetic acid solution, in a volume ratio (chitosan : snail slime) 70 : 30, the material is insoluble in water for several weeks.
- a cross-linked film is thus obtained without using other chemical components.
- the use of the material secreted by a gastropod, in particular snail slime, can lead to cross- linked films.
- the presence of cross-linking may be evaluated by any method known in the art. For example, it may be evaluated by measuring the solubility of the film, wherein a film that is insoluble in water for several weeks comprises a cross-linked polymer.
- said hyaluronate salt is sodium hyaluronate.
- said gastropod is a slug or a snail. Still preferably, said gastropod is selected from the group consisting of: Helix aspersa, HelixComplex , Helix Pomatia, Helix Vermiculata, Helix aperta, Helix albescens, Helix ceratina, Helix engaddenis, Helix godetiana, Helix lucorum Linnaeus, Helix lutescens, Helix melanostomata, Helix obruta, Helix pomatia, Helix texta, Cornu Aspersum, Theba pisana, Otala Lactea, Cernuella virgata, Capaea, Euglandina rosea , Achatina fulica, Helix lucorum, Rapana venosa, Macrochlamys indica and Arion subfuscus.
- said material secreted by a gastropod is snail slime.
- the film of the invention further comprises:
- the film as defined above comprises nanoparticles for modulating the permeability and/or other micro/nanoparticle systems to modulate the release of the active substance and increase skin permeability.
- said micro/nanoparticulate system comprises or consists of mica, clay, or montmorillonite particles.
- said cosmetic and/or therapeutic agent is selected from the group consisting of: antifungal agent, antibacterial agent, antiprotozoal agent, antiviral agent, keratolytic agent, exfoliating agent, anti-inflammatory agent, analgesic agent, anaesthetic agent, antiseptic agent, antihistamine agent, anti-scabies agent, antioxidant agent, a proteolytic enzyme, natural alkaloid, agent for the treatment of onychophagy and agent that stimulates the proliferation of fibroblasts.
- agent for the treatment of onychophagy refers to a substance with an unpleasant taste, for example bitter and/or spicy.
- an agent for the treatment of onychophagy is an enamel and/or a solution comprising denatonium benzoate.
- Another example of an agent for the treatment onychophagy according to the present invention is a plant extract with a strong bitter and/or spicy taste, such as for example a gentian or rhubarb extract.
- said antifungal agent is an antimycotic of the azole and imidazole drug family.
- said cosmetic and/or therapeutic agent is selected from the group consisting of: fluconazole, econazole, 1,3,7-trimethylxanthine, sodium hyaluronate, citric acid, glycerol, miconazole, ketoconazole, clotrimazole, itraconazole, terbinafme, lidocaine, procaine, xylocaine, lidocaine hydrochloride, cortisone, cortisone derivative, promethazine, diphenhydramine hydrochloride, desclofeniramine maleate, catalase, erythromycin, tetracycline, gentamicin, neomycin, bacitracin, silver sulfadiazine, silver salt, chlorhexidine, chloramphenicol, thymol, acyclovir, permethrin, salicylic acid, diclofenac, ibuprofen, tea extract, aloe extract, tea tree oil, Op
- said cortisone derivative is hydrocortisone acetate or triamcinolone acetonide.
- said vitamin is selected from the group consisting of vitamin A, vitamin D, vitamin E, vitamin K and a mixture thereof.
- the film of the invention comprises an antifungal agent such as fluconazole.
- the film of the invention is characterized by any one or more of the following parameters:
- - stress at break (o b ) from 0.1 to 100 MPa (preferably from 0.5 to 95 MPa or from 0.2 to 60 MPa),
- e b - elongation at break (e b ) from 1 to 2000% (preferably from 1 to 150% or from 8 to 200%),
- E Young modulus
- o m maximum stress
- - detachment force (F) equal to or higher than 1 N (preferably equal to or higher than 2 N or than 3 N or than 4 N, preferably from 4 to 20 N or from 4 to 18 N),
- T ⁇ ,oo is the transmittance at 600 nm and X is the thickness of the film
- T% f/Io x 100
- an X-ray diffraction pattern comprising a broad halo at 20 from 15° to 25° measured using CuKa radiation (optionally 40 mA, 40 kV, and 1.5 A), and/or
- WVP water vapour permeability
- said detachment force is defined as the force required to detach a film that has adhered to a surface, such as skin, glass or aluminum.
- Said detachment force can be measured with any method known in the art, for instance using a rheometer or a dynamometer, e.g. by applying the film to the surface with a force of 5 N for 30 s, then raising the plunger at 1 mm/s.
- these parameters depend on several factors, such as polymer used and its amount, degree of drying of the film, storage time, etc. Further, it is to be understood that the polymer of the invention may be characterized by any combination of such parameters. Additionally, it is to be understood that any method known in the art may be used to measure such parameters, the methods described in the Examples being preferably used.
- the film does not alter cell viability or cell proliferation compared to a proper control, such as untreated cells.
- Cell viability and proliferation may be measured according to any known method, in particular those described in the Examples below.
- the film is not cytotoxic. Cytotoxicity may be measured according to any known method, for example by measuring the production/release of lactate dehydrogenase (LDH) in vitro. Then, the film of the invention preferably does not induce/stimulate/cause LDH production compared to a proper control, such as untreated cells or cells treated with a known cytotoxic agent such as phenol.
- a proper control such as untreated cells or cells treated with a known cytotoxic agent such as phenol.
- the film improves wound healing. Improvement of wound healing may be measured by any known method, for instance in vitro by the production/release of fibroblast growth factor (FGF) and/or collagen type 1 (COL1) by cells.
- FGF fibroblast growth factor
- COL1 collagen type 1
- the film of the invention preferably increases FGF and/or COL1 production compared to a proper control, such as untreated cells or cells treated with a known cytotoxic agent such as phenol.
- the film is antibacterial, particularly effective against Gram-positive and/or Gram-negative bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae.
- Antibacterial effect may be measured by any known method, including the Kirby-Bauer (KB) diffusion test, e.g. as described in EUCAST: The European Committee on Antimicrobial Susceptibility Testing, Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 6.0, 2016. http://www.eucast.org.
- the antibacterial effect may be measured as described below.
- the film is said to be antibacterial when, after an appropriate incubation time of for example about 24 h at 25 to 40 °C in a Mueller-Hinton agar plate pre-loaded with a bacterium, a halo appears around the film.
- any one or more of the agents in the film penetrates the surface on which the film is adhered, such as skin, mucosa, nail, lip, etc. Surface penetration may be measured by any known method, e.g. using a Franz Cell system, such as by a permeation study performed as described in the Examples below.
- An object of the present invention is a procedure for the preparation of a film comprising the steps of:
- an object of the present invention is a procedure for the preparation of a film comprising the steps of:
- said material is slime, mucus or gastropod extract.
- said step b) is performed by leaving said solution to evaporate or by heating it.
- the total volume of said solution is comprised between 10 ml and 30 ml or between 15 ml and 25 ml.
- the volume of said solution is of approximately 20 ml.
- any one of said procedures comprises a further step c) after step al) or a2) or a3) and before step b), said further step c) being: pouring said solution in a Petri dish.
- the diameter of the Petri dish is comprised between 2 cm and 10 cm, between 5 cm and 9 cm or between 5.5 cm and 8.5 cm.
- the volume of solution that is poured in the Petri dish is comprised between 5 and 10 mL, preferably it is of approximately 7.4 mL.
- the weight of solution that is poured in the Petri dish is comprised between 5 and 15 mL, preferably it is of approximately 10.2 g.
- any one of said procedures comprises a further step d) after said step b), said further step d) being: depositing a cross-linking agent on the film.
- said cross- linking agent is a 0.1% w/V aqueous solution of sodium hyaluronate.
- said solvent is water.
- said water is acidified.
- said solvent is acid.
- said polymer is soluble in acidic environment, for example when said polymer is chitosan, said water is acidified.
- said polymer is gelatine, said water is not acidified.
- said acidified water is acidified with hydrochloric acid, acetic acid, lactic acid or citric acid.
- an acidic pH of the solution is preferred, while for other skin applications and wound healing a pH > 6 is preferred.
- the pH of the material secreted by a gastropod and polymer solution can be determined and varied by adding an acid or a base before evaporation.
- said polymer is in a concentration equal to or greater than 0.1% w/V with respect to the volume of said solution. In a preferred form of any one of said procedures, said polymer is in a concentration equal to or lower than 45% w/V or than 10% w/V or than 5% w/V with respect to the volume of said solution. In a further preferred form of any one of said procedures, said solution comprises from 5% to 100% in terms of volume of said material secreted by a gastropod. Preferably, in any one of said procedures, said solution comprises from 5% to 99.9%, from 20% to 80%, from 30% to 70%, from 40% to 60% or about 50% in terms of volume of said material secreted by a gastropod.
- said solution comprises approximately 100%, 70%, 60%, 50%, 40%, 30% or 15% in terms of volume of said material secreted by a gastropod. It is to be understood that the remaining volume of said solution comprises or consists of the polymer dissolved in the solvent. Likewise, it is to be understood that additional agents (e.g. an acid, a base, an excipient such as glycerol, etc.) can be added to the solution at any phase of the procedure prior to evaporation (step b), for instance to the polymer dissolved in the solvent, to the material secreted by a gastropod or to the obtained solution.
- additional agents e.g. an acid, a base, an excipient such as glycerol, etc.
- the film of the invention is obtainable from any one of the procedures defined above employing the following parameters:
- the % w/V of polymer is reported as weight of polymer / total volume of solution; the % V/V of solvent is reported as V of solvent / total volume of solution; the % V/V of material secreted by a gastropod is reported as V of material secreted by a gastropod (when step al) or a2) was employed) or V of water (when step a3) was employed) / total volume of solution.
- the invention also provides the film obtainable by subjecting CS 7030 A, CS_3070_A or CS_3070_SOL to step d) as defined above using a 0.1% w/V aqueous solution of hyaluronate.
- the film as defined above for use as a medicament.
- the film as defined above is for use in a method of preventing and/or treating: a dermatological disorder, a cutaneous wound, an aphtha, an infection, dermatitis, atopic dermatitis, radiotherapy dermatitis, eczema, rash, acne vulgaris, psoriasis, rosacea, a burn, a sunburn, an ulcer, a diabetic ulcer, a scald, onychomycosis, onychophagia and/or a periodontal disease.
- said infection is fungal, bacterial or viral.
- said infection is a vaginal infection, a buccal infection, a skin infection, a nail infection, a mucosal infection, a lip infection, a wound infection.
- said infection is selected from the group consisting of: a vaginal infection, a buccal infection, a skin infection, a nail infection, a viral infection of the skin, a viral infection of the mucosa, a viral infection of the lips, a bacterial infection of the skin, a bacterial infection of the mucosa, a fungal infection of the skin, an infection of a wound, a vaginal herpes, a lip herpes or cold sores.
- said film as defined above for use as an antibacterial, antifungal and/or antiviral agent.
- said antibacterial agent is effective against Gram positive and/or a Gram negative bacteria, preferably, said bacteria are selected from the group consisting of: Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and combinations thereof.
- said antifungal agent is effective against a fungus of the Candida genus, including but not limited to: Candida albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei.
- the use of the film as defined above as a cosmetic product is also an object of the invention.
- the use of the film as defined above for packaging food is also an object of the invention.
- the use of the film as defined above for food storage is also an object of the invention.
- a further object of the invention is a non-therapeutic cosmetic method for preventing and/or decreasing a skin imperfection (or skin blemish), hydrating/moisturizing the skin and/or soothing the skin or mucosa, said method comprising the administration and/or application of the film as defined above.
- said skin imperfection (or skin blemish) is cellulite, a stretch mark, a wrinkle, a scar, a stain and/or redness of the skin.
- the present invention provides a kit comprising the film as defined above.
- the present invention provides a wrap or foil comprising the film as defined above.
- said wrap or foil is a wrap or foil for the storage and/or packaging of food. Accordingly, the present invention provides the use of said wrap or foil for storing and/or packaging food.
- the present invention provides a patch comprising the film as defined above.
- the present invention provides a mask comprising the film as defined above.
- the present invention provides a gauze comprising the film as defined above.
- the present invention provides a drug delivery system comprising the film as defined above.
- the present invention provides a system comprising at least two films, said films being as defined above.
- the present invention provides a system comprising at least a first film and a second film, said first film and said second film being as defined above.
- the polymer in the first film is different from the polymer in the second film.
- said first and said second films further comprise a cosmetic and/or therapeutic agent.
- the cosmetic and/or therapeutic agent in the first film is different from the cosmetic and/or therapeutic agent in the second film.
- a solution comprising a polymer and a material secreted by a gastropod, wherein said polymer is in a concentration equal to or greater than 0.1% w/V compared to the volume of said solution, wherein said material is slime, mucus, or gastropod extract, and wherein said material is fresh or lyophilised.
- a solution comprising a polymer and a material secreted by a gastropod, wherein said solution comprises from 5% to 100% in terms of volume of said material secreted by a gastropod, wherein said material is slime, mucus, or gastropod extract, and wherein said material is fresh or lyophilised.
- a solution comprising a polymer and a material secreted by a gastropod, wherein said polymer is in a concentration equal to or greater than 0.5% w/V compared to the volume of said solution, wherein said solution comprises from 5% to 100% in terms of volume of said material secreted by a gastropod, wherein said material is slime, mucus, or gastropod extract and wherein said material is fresh or lyophilised.
- said solution comprises from 5% to 100% in terms of volume of said material secreted by a gastropod.
- said solution comprises from 5% to 99.9%, from 20% to 80%, from 30% to 70%, from 40% to 60% or about 50% in terms of volume of said material secreted by a gastropod.
- said solution comprises approximately 100%, 70%, 60%, 50%, 40%, 30% or 15% in terms of volume of said material secreted by a gastropod.
- the remaining volume of said solution comprises or consists of the polymer dissolved in the solvent.
- additional agents e.g. an acid, a base, an excipient such as glycerol, etc.
- the material secreted by the gastropod in pure (liquid) form can be used 100% (v/v): in this case the polymer (in powder form) and any other excipients are inserted directly into the material secreted by the gastropod, which can optionally be considered as the only solvent. Otherwise, the volume of the material secreted by a gastropod can be decreased and then mixed with a polymer solution at different v/v ratios (5:95 to 95:5, respectively).
- the slime is used as a lyophilised powder it can be inserted into the preparation solvent from 5% to 100% w/V, in particular from 5% to 99.9%, preferably from 5% to 95% w/V.
- the solution obtainable from step al), a2) or a3) of any one of the procedures as defined above is obtainable employing the parameters reported in the table above (i.e. table describing the film of the invention obtainable from any one of the procedures defined).
- the present invention provides a kit comprising the solution as defined above.
- the present invention provides a wrap or foil comprising the solution as defined above.
- said wrap or foil is a wrap or foil for the storage and/or packaging of food. Accordingly, the present invention provides the use of said wrap or foil for storing and/or packaging food.
- the present invention provides a patch comprising the solution as defined above.
- the present invention provides a mask comprising the solution as defined above.
- the present invention provides a gauze comprising the solution as defined above.
- the present invention provides a drug delivery system comprising the solution as defined above.
- the film is administered to the skin, oral mucosa (particularly gums), vaginal mucosa, anal mucosa.
- composition of the invention is administered to a human subject or an animal subject.
- the film of the invention is a composition comprising a polymer and a material secreted by a gastropod as defined above, said composition being in the form of a film.
- Dosage forms for topical administration are generally classified as liquid, semisolid, and solid, as outlined in Figure 1 (taken from: Brown MB., Turner R., Lim ST. Topical product development, In: Transdermal and topical drug delivery. Principles and Practice. Edited by Benson HAE., Watkinson AC., Wiley 2012, pp. 255-286, herein incorporated by reference).
- a dermal patch or film may be an alternative (C. Padula et al. Eur. J Dermatol., 17(4) (2007), pp. 309-312).
- Films can be classified as patches, but unlike medicated patches (plasters or cataplasms), they do not require, but may include, external support. These are therefore polymeric materials that can be applied directly to the skin (or mucosa or nail or elsewhere) with a light pressure.
- films per se do not have a support (backing sheet, which can be made of non-woven fabric or other non-occlusive or occlusive material).
- transdermal patches normally consist of an outer covering which supports a preparation which contains the active substance(s).
- the outer covering is a backing sheet impermeable to the active substance(s) and normally impermeable to water, designed to support and protect the preparation.
- European Pharmacopoeia 10 Ed. European Pharmacopoeia 10 Ed.
- the film components meaning the solution/dispersion comprising polymer and material secreted by a gastropod before drying
- Films for topical use are generally thin, highly flexible dosage forms of a squared/rectangular shape and easily applicable even without the use of applicators. They are usually formulated with the active ingredient of interest together with water-soluble polymers, plasticisers (polyethylene glycol, glycerol, etc.), humectants (glycerol or other polyols), diluents, and/or additional substances that prevent microbial proliferation and/or increase the permeability of the drug into the skin and/or control its release over time. In the invention it is therefore possible to formulate films that solubilize and release the active ingredient and all functional components (bioactive polymers and material secreted by a gastropod) very quickly.
- the films of the invention can be broken up thus releasing snail slime.
- the film once the film is adhered to the skin, it can remain as such for the required period of time releasing the active components contained therein, and eventually be washed.
- the film when applied to mucous membranes the film solubilizes more or less quickly depending on the formulation.
- a further object of the invention are cross-linked polymers-based films that do not solubilize, which can be combined with rapidly solubilizing films in order to create a controlled release system.
- Films are solid but flexible dosage forms that adhere to the skin due to the presence of an adhesive substance and that, depending on the composition, can be removed at the end of application or dissolved more or less quickly in situ.
- a further feature of films is that, unlike medicated patches, they can be formulated as easily removable by washing the skin and this is an advantage when the film is applied to damaged skin.
- the film may be applied under occlusive conditions, exploiting the occlusion enhancing effect on drug administration.
- the films may also be applied to mucous membranes (e.g., oral, vaginal) by appropriately modifying the formulation to control the disintegration of the film.
- mucous membranes e.g., oral, vaginal
- the at least one polymer as defined above is not toxic or irritating, does not release impurities, is wettable and tensile resistant.
- the type of polymer employed, and its molecular weight can greatly affect the properties of the films and their disintegration/solubilization time.
- Chitosan is a linear polysaccharide composed of D-glucosamine and N-acetyl-D- glucosamine bound through b bonds.
- Chitosan is derived from chitin, which is mainly derived from shells of crustaceans and molluscs, but also from fungi.
- chitosan may be low, medium or high molecular weight and exhibit a deacetylation degree for example from 5 to 98%, preferably equal to or greater than 93%.
- the molecular weight of chitosan may be, for example, from 40000 to 500000 MW or of approximately 100 KDa.
- Gelatine is a protein obtained from the processing of collagen.
- the gelatine is cross-linked with naturally occurring and non-toxic agents, such as for example gallic acid, ferulic acid, and citric acid.
- Gelatine can be classified by, for example, the Bloom index, which is a measure of the stiffness of the gel it forms under certain conditions.
- gelatine may have a Bloom index e.g., from 20 to 300 Bloom.
- the cross-linking degree is measured spectrophotometrically, after derivatization of the e-amino groups of lysines, present in the macromolecular chain, with an appropriate reagent (trinitro-benzenesulfonic acid) Ofner CMIII, Bubnis WA, Chemical and swelling evaluation of amino group crosslinking in gelatine and modified gelatine matrices. Phar. Res. 1996; 13: 1821-7.
- Cellulose is a polysaccharide in which glucose units are bound by a b 1 4 glycosidic bond.
- Cellulose polymers are divided into subclasses with very different characteristics. All polymers belonging to such subclasses may be used in the films of the invention.
- films may comprise cellulose derivatives: hypromellose with different molecular weight and/or of different percentage content of methoxyl and/or hydroxypropyl groups (such as that used in the Examples); as well as any cellulose derivative, such as hydroxyethylcellulose, hydroxypropylcellulose, methyl cellulose, carboxymethylcellulose and sodium carboxymethylcellulose.
- HPMC hydroxypropylmethylcellulose
- HPMC 2910 HPMC 2910, USP
- Methocel F HPMC 2906, USP
- Methocel K HPMC 2208, USP
- Another HPMC classification parameter is the viscosity of 2% w/V Methocel solutions in water, measured at 20 °C: thus Methocel E is designated as E5, El 5 or E50 because the relative solutions have viscosity values of 5 mPa s, 12-15 mPa s and 40-56 mPa s, respectively.
- Starch consists of two families of homopolysaccharides, amylose and amylopectin. The first is comprised of glucose chains with alpha 1-4 bonds while the second is comprised of alpha 1-4 glucose chains with branches in alpha 1-6 bonds at the branching point. The relationship between these two families indicates the molecular weight.
- Keratin is a polymer that can be extracted from wool.
- Gastropods are a class of molluscs comprising more than 65000 species and include both snails (Helix) and slugs (Limax).
- Helicidae such as: Helix Pomatia and Helix Aspersa (the most common) as well as Helix Complex, Helix Vermiculata, Helix aperta, Helix albescens, Helix ceratina, Helix engaddenis, Helix godetiana, Helix lucorum Linnaeus, Helix lutescens, Helix melanostomata, Helix obruta, Helix pomatia, Helix texta, Cornu Aspersum, Theba pisana, and Otala Lactea (synonym Helix ahmarina or Helix lactea).
- Examples of gastropods also include Cernuella virgata, Capaea , and Euglandina rosea. In the present
- invertebrate zoology manuals are references to the description of the Gastropoda class: Evolutionary Developmental Biology of Invertebrates vol 2 ED. Springer; The Invertebrates: Volume VI Mollusca I, di Libbie H. Hyman 1967 and Invertebrate Zoology of EE. Ruppert and RD. Barnes ED Saunders College Pub, International ed 1994 VI edition and are herein incorporated by reference.
- gastropods commonly called“snail slime” is produced by salivary glands (pedal glands) and the main molecules present therein are: allantoin, glycolic acid, collagen, elastin, exfoliating lactic acid, mucopolysaccharides (GAGs and without sulfur incorporation), vitamins A, C, E, B1 and B6, free amino acids, peptides, proteins, enzymes, molecules with antiprotease activity (from the Italian heliciculture institute website www.istitutodielicoltura.it).
- the composition and function of materials secreted by a gastropod are described in the following publications, herein incorporated by reference: G. Cilia and F. Fratini, J. Complementary Integr. Med., 2018, 20170168 and C. Trapella et al. Scientific Reports, 2018, 8, 176665.
- Slime allows snails to move, and thanks to its adhesive properties it allows a movement even on vertical or particularly complex surfaces. Slime is also produced to keep the body of the gastropod lubricated, hydrated and moistened but also as a defence from predators.
- An extract of a gastropod refers to the entire body of a gastropod that has been blended.
- pure or“fresh” material secreted by a gastropod, it is meant a material secreted by the gastropod, not further treated/processed.
- dry or“lyophylised” or“freeze-dried” material secreted by a gastropod it is meant that the material as secreted by the gastropod has been treated/processed, in particular by lyophilization.
- the material secreted by a gastropod can be obtained by known techniques, for example as described in US 5,538,740, WO201311371 and IT 10207000117547, herein incorporated by reference. Particularly, the material secreted by a gastropod may be obtained by the Miiller method. Alternatively, the material secreted by a gastropod can be extracted with manual stimulation as indicated in the Helidermine products (http://www.helidermina.com/).
- WO 2013011371 Al was employed for the film compositions reported in Tables 5 and 6.
- the material secreted by a gastropod using the Miiller method was kindly supplied by Azienda Agricola I PODERI - Azienda Agricola - Elicicoltura, Poderi di Montemerano 58014 Manciano (GR).
- snail slime After extraction using the Miiller method, snail slime can be stored until further use as such (pure or fresh) or after freeze-drying in the optional presence of a lyoprotectant such as dextran. Storage of the fresh or dried snail slime can be carried out at -25°C to 5°C.
- the material secreted by a gastropod in particular snail slime
- a gastropod in particular snail slime
- the material secreted by a gastropod can be preferably characterised by the features reported in the following table.
- M.I.M. stands for Multiple Ion Monitoring mode.
- Cosmetic and/or therapeutic agents i.e. drugs
- the following agents may be inserted into the films: fluconazole/econazole (antifungals of the azole and imidazole drug family), 1,3,7-trimethylxanthine (caffeine, natural alkaloid), lidocaine hydrochloride (local anaesthetic).
- Further agents that may be inserted into the films include: cortisone derivatives (e.g. hydrocortisone acetate, triamcinolone acetonide, etc.); antihistamines (e.g.
- promethazine diphenhydramine hydrochloride, desclopheniramine maleate, etc.
- proteolytic enzymes e.g. catalase, etc.
- antibacterials e.g. erythromycin, tetracyclines, gentamicin, neomycin, bacitracin, silver sulfadiazine or other silver salts, chlorhexidine, chloramphenicol, thymol, etc.
- antivirals e.g. acyclovir, etc.
- anti-scabies e.g. permethrin, etc.
- antifungals e.g.
- fluconazole fluconazole, econazole, miconazole, ketoconazole, clotrimazole, itraconazole, terbinafms, etc.
- local anaesthetics e.g. lidocaine, procaine, xylocaine, etc.
- keratolytics e.g. salicylic acid, etc.
- anti inflammatories and analgesics e.g. diclofenac, ibuprofen, etc.
- active substances of natural origin include: tea extracts, aloe extracts, tea tree oil, Opuntia Ficus Indica extract, vitamins (e.g., Vitamin A, D, E, K); amino acids and other substances capable of stimulating fibroblast proliferation (e.g. cysteine, glycine, teronine, hyaluronate, growth factors).
- vitamins e.g., Vitamin A, D, E, K
- amino acids and other substances capable of stimulating fibroblast proliferation e.g. cysteine, glycine, teronine, hyaluronate, growth factors.
- said excipient is selected from the group consisting of: plasticizer, diluent, humectant, pH modifier (e.g. an acidifier or a basic substance), absorption promoter, fragrance, solubilizer, emulsifier, antioxidant, dye, preservative, nanoparticle, microparticle, a humectant, and a combination thereof.
- said plasticizer is polyethylene glycol or glycerol or polyethylene oxide.
- said humectant is glycerol, sorbitol, propylene glycol, or polyethylene glycol.
- Said pH modifier may be for example a 1M NaOH solution.
- Absorption promoters include, for example, glycols, alcohols, surfactants.
- Said emulsifier is preferably a non ionic surfactant or a polysaccharide.
- Said antioxidant can be an alkyl-gallate or a tocopherol, for example.
- said excipient is a nanoparticle for modulating film permeability or a micro/nanoparticulate system for modulating the release of the active substance and increasing skin permeability.
- said nanoparticle may be mica, clay or montmorillonite.
- said excipient is glycol.
- FIG. 4 Exemplary stress-strain curves recorded on chitosan films prepared in (I) acetic acid (A); (II) lactic acid (L) and (III) snail slime (SOL).
- B Exemplary stress-strain curves obtained for GB and GBS 3070 bovine gelatine films.
- C Exemplary stress-strain curves obtained for E5, E5S 7030 and E5S 3070 cellulose films.
- D Exemplary stress- strain curves obtained for CMC -based films (CMC, CMCS_3070 and CMCS_100 films).
- A Application to the inside of the palm of the hand, at the joining of thumb and forefinger.
- FIG. 6 An INSTRON 4465 dynamometer detail, during the detachment measurement of the CS 3070 A film applied to porcine skin.
- Figure 7. Adhesive properties of chitosan-based films (***p ⁇ 0.001, **p ⁇ 0.01, *p ⁇ 0.05). Statistical analysis was performed with Graph Pad Prism 4. One-way analysis of variance (ANOVA) followed by Tukey's Multiple Comparison Test was employed to assess statistical significance of the experimental conditions; statistically significant differences were determined at p ⁇ 0.05.
- Figure 9 Proliferation measurements obtained using VERO cells for films produced with: chitosan only (C_A in grey), chitosan: slime 30:70 (CS_30:70_A in black), chitosan solubilised directly in snail slime (CS_3070_SOL in white). Cell viability is expressed as percent proliferation relative to control cells (grown in normal medium).
- Figure 10 Vero cell viability after 48 h of incubation with the media containing film components following disks dissolution. Data (mean values ⁇ SD) are relative to the untreated control grown in normal medium (set to 100%).
- FIG. 14 Apple slices wrapped with CMCS_3070 film. Photo taken 2 days after application.
- Figure 15 Permeation of Fluconazole (FL) across porcine skin.
- “FL film” is a 5% w/V porcine gelatin-based film containing snail slime, glycerol (30 % w/w on the dry polymer) and FL (5% w/w with respect to the total dry mass of gelatin, glycerol and snail slime, where gelatine : snail slime volume ratio 30 : 70).
- “FL solution” is a control solution of FL 0,45% w/V in phosphate buffer supplemented with 20% w/V ethanol.
- FIG. 16 X-rays diffraction patterns (left) and corresponding IR spectra (right) of chitosan films and lyophilized solution.
- A left: X-rays diffraction patterns of Chitosan films prepared by dissolving chitosan in acetic acid and containing different amounts of Snail slime; right: infrared spectra acquired on the same samples
- B left: X-rays diffraction patterns of Chitosan films prepared by dissolving chitosan in lactic acid and containing different amounts of Snail slime; right: infrared spectra acquired on the same samples
- C left: X-rays diffraction patterns of Chitosan films prepared by dissolving chitosan directly into snail slime and containing different amounts of high purified water (HPW); right: infrared spectra acquired on the same samples
- D left: X-rays diffraction patterns collected on lyophilized snail slime
- E5 and E50 hydroxypropyl methylcellulose (HPMC) (Methocel E5 and E50)
- FDS freeze-dried snail slime
- H2 Hyaluronate 2% w/V
- SOL product wherein the polymer has been directly solubilized in the snail slime and water has been subsequently added
- Exemplary films of the invention are labelled using the following nomenclature.
- the first abbreviation indicates the polymer used, namely: chitosan (C), porcine gelatin (GP), bovine gelatin (GB), hydroxypropyl methylcellulose E5/E50 (E), sodium carboxymethyl cellulose (CMC) and/or sodium hyaluronate (H).
- the letter “S” indicates the presence of snail slime.
- the abbreviation “Gly” indicates the addition of glycerol, while the abbreviation “SOL” indicates that the polymer (e.g. chitosan) was dissolved directly in the snail slime and the mixture thus obtained was subsequently added with water.
- HCl For the chitosan-based films, "HCl”, “A”, and “L” indicate, respectively, that the polymer is solubilized in an aqueous solution acidified with hydrochloric acid, acetic acid and lactic acid. "H” as a final letter and “CA” indicate crosslinking of the polymer with hyaluronate and citric acid, respectively.
- S or FDS snail slime
- GBS 7030 indicates that the film was obtained from a solution containing 70 parts by volume of an aqueous bovine gelatine solution and 30 parts by volume of snail slime.
- films E5S_100, E50S_100, CMCS _100, HS_100, HS_100 Gly contain the polymer directly solubilized in the snail slime, which corresponds to the final volume.
- Glycerol (Gly) has been added as percent in weight (w/w, weight of glycerol with respect to the weight of dry polymer) or as a percent in volume (V/V, volume of glycerol with respect to the total volume of the solution).
- compositions of exemplary films are provided.
- Tables 1-6 show the compositions of some films, as examples of the present invention.
- the films were prepared using the following polymers: chitosan (C), chitosan (C) cross-linked with sodium hyaluronate (H), porcine gelatine (GP), bovine gelatine (GB), porcine gelatine (GP) cross-linked with citric acid (CA), bovine gelatine (GB) cross-linked with citric acid (CA), hydroxypropylmethylcellulose (E), sodium carboxymethyl cellulose (CMC), sodim alginate (AL), sodium hyaluronate (H) and finally mixtures of CMC and H.
- Such polymers may be used at different concentrations (% w/V with respect to the total volume of the polymer-slime solution) relatively to the molecular weight of the polymer itself.
- Table 1 Compositions of chitosan-based films (1 and 2% w/V)
- Table 3 Compositions of cellulose-based films (2 and 5% w/V)
- chitosan-based films were prepared at a concentration of 1% and 2% w/V chitosan with respect to the total volume of the solution (i.e. 200 mg chitosan or 400 mg chitosan in 20 ml solution, respectively).
- the 200 mg of chitosan in case of film with 1% w/V chitosan
- the 200 mg of chitosan are solubilized in a volume of acidified HPW lower than the 20 ml of the total solution volume according to the V/V ratio of added slime as described in Table 1.
- CS_7030 films 6 ml are slime and 14 ml are chitosan in 1% w/V acid solution, while in CS_3070 films the millilitres of slime are 14 and those of chitosan in 1% w/V acid solution are 6, as indicated in Table 1.
- HC1 Acetic Acid, and Lactic Acid
- 6M HC1 it has been observed that the solubilisation of chitosan occurs fairly quickly as opposed to when using Acetic Acid or Lactic Acid in which the solution was heated to 37 °C or 30 °C for two hours.
- Acetic Acid, and Lactic Acid were used for chitosan solubilisation.
- Direct solubilisation in pure snail slime involved times comparable to those obtained using HC1.
- solubilisation of chitosan requires different times depending on the amount of acid water that is added: the higher the initial concentration, the longer the time required for solubilisation.
- gelatines of different origins may be used.
- a gelatine extracted from porcine skins (Sigma, 300 Bloom) and one of bovine origin (Sigma, 225 Bloom) are used. The preparation method followed for both is the same, therefore a unique description is given in the same paragraph.
- the exemplary gelatine-based films were prepared at a concentration of 5% w/V gelatine with respect to the total volume of the solution (i.e. 1 g of gelatine in 20 ml solution). It should be understood that other concentrations of gelatine, in particular from 0.5 to 40% w/V, could be used.
- the 1 g of gelatine is solubilized in a volume of HPW lower than the 20 ml of total solution volume according to the V/V ratio of added slime as described in Table 2.
- hydroxypropyl methylcellulose HPMC E5 and E50 (Dow Chemical Company, USA) and sodium carboxymethyl cellulose (CMC, ACEF Piacenza, Italy) were used, but other types of cellulose could also be used.
- the exemplary cellulose-based films were prepared at a concentration equal to 5% w/V of E5 and E50 (i.e. 1 g of E5 or E50 in 20 ml of solution) and equal to 2% w/V of CMC (i.e. 400 mg of CMC in 20 ml of solution) with respect to the total volume of the solution.
- concentrations of cellulose could also be used, for example from 0.1 to 15% w/V for E5 and from 0.5 to 3% w/V for CMC.
- 1 g of E5, 1 g of E50 or 400 mg of CMC is solubilized in a volume of HPW lower than 20 ml or equal to the total volume of the solution according to the V/V ratio of added snail slime, as described in Table 3.
- 1 g of E5, 1 g of E50 or 400 mg of CMC is solubilized in 20 ml of snail slime.
- sodium alginate (Fluka) was used at a concentration of 1% w/V, with respect to the total volume of the solution (i.e. 150 mg of AL in 15 ml of solution). Other concentrations of alginate could also be used, for example from 0.5 to 3% w/V.
- 150 mg of AL are solubilized in a volume of HPW lower than 15 ml, according to the V/V ratio of added snail slime, as described in Table 4.
- sodium hyaluronate (ACEF spa, Italy) was used at a concentration of 1% w/V, with respect to the total volume of the solution (i.e.
- 150 mg of H in 15 ml of solution 150 mg of H in 15 ml of solution.
- Other concentrations of hyaluronate could also be used, for example from 0.1 to 2% w/V.
- 150 mg of H are solubilized in a volume of HPW lower than 15 ml, according to the V/V ratio of added snail slime, as described in Table 5.
- 150 mg of H are solubilized in 15 ml of snail slime.
- CMC carboxymethyl cellulose
- Hyaluronate ACEF spa, Italy
- concentration was varied between 0.3-2% w/V, with respect to the total volume of the solution (i.e. 400 mg of CMC in 20 ml of solution).
- concentrations of cellulose could also be used, for example from 0.5 to 3% w/V.
- the solid polymers (CMC and H) are directly solubilised in snail slime.
- sodim hyaluronate (1650 kDa, ACEF spa, Italy);
- cellulose as sodium CMC (medium viscosity, ACEF, Piacenza, Italy);
- Example 1 Procedure for the preparation of non-cross-linked chitosan-based films (1% w/V) by acidification with 6M HCl
- C_HC1 film Chitosan-based films were prepared by dissolving 200 mg of chitosan FG90 (100 kDa Faravelli, Italy) (1% w/V) in 20 mL of high purified water acidified with 6M HCl (0.75% v/v). 7.4 mL of this solution were poured into a PE (polyethylene) petri dish (5.5 cm diameter): the film is obtained by solvent evaporation (solvent casting) under a laminar hood at room temperature overnight.
- PE polyethylene
- CS_7030_HC1 films The CS_7030_HC1 films were prepared by dissolving 200 mg of chitosan in 14 ml of high purified water acidified with 6M HCl (the volume of HCl is kept constant as in C HCl). Subsequently, after complete solubilisation of chitosan, which took place by stirring, 6 ml of (pure) slime were added and the mixture was allowed to stir for further 10 minutes. Finally, 7.4 ml of this mixture were poured into a 5.5 cm diameter PE petri dish. The film is obtained by evaporating the solvent under laminar hood at room temperature overnight.
- CS_3070_HC1 films The CS_3070_HC1 films were prepared by dissolving 200 mg of chitosan in 6 ml of high purified water acidified with 6M HCl (the volume of HCl is kept constant as in C HCl). Subsequently, after complete solubilisation of chitosan, which took place by stirring, 14 ml of (pure) slime were added and the mixture was allowed to stir for further 10 minutes. Finally, 7.4 ml of this mixture were poured into a 5.5 cm diameter PE petri dish. The film is obtained by evaporating the solvent under laminar hood at room temperature overnight.
- Example 2 Procedure for the preparation of non-cross-linked chitosan-based films (1% w/V) by acidification with 1% v/v acetic acid
- C_A film Chitosan-based films were prepared by dissolving 200 mg of chitosan (1% w/V) in 20 mL of an aqueous solution of 1% v/v acetic acid. The solution was maintained under stirring for two hours at 30 °C until complete dissolution of the chitosan. Finally, 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- CS_8515_A film The CS_8515_A films were prepared by dissolving 200 mg of chitosan in 17 ml of 1% v/v acetic acid acidified aqueous solution. The solution was maintained under stirring for two hours at 30 °C until complete dissolution of the chitosan. 3 ml of slime were added to the solution and the mixture was kept under stirring for further 10 minutes. Finally, 7.4 mL of mixture were poured into a PE petri dish (5.5 cm diameter): the film was obtained after evaporation of the solvent under laminar hood at room temperature overnight.
- CS_7030_A film The CS_7030_A films were prepared by dissolving 200 mg of chitosan in 14 mL of 1% v/v acetic acid acidified aqueous solution. The solution was maintained under stirring for two hours at 30 °C until complete dissolution of the chitosan. 6 ml of slime were added to the solution and the mixture was kept under stirring for further 10 minutes. Finally, 7.4 mL of mixture were poured into a PE petri dish (5.5 cm diameter): the film was obtained after evaporation of the solvent under laminar hood at room temperature overnight.
- CS_3070_A film The CS_3070_A films were prepared by dissolving 200 mg of chitosan in 6 mL of aqueous solution acidified with 1% v/v acetic acid. The solution was maintained under stirring for two hours at 30 °C until complete dissolution of the chitosan. 14 ml of slime were added to the solution and the mixture was kept under stirring for further 10 minutes. Finally, 7.4 mL of mixture were poured into a PE petri dish (5.5 cm diameter): the film was obtained after evaporation of the solvent under laminar hood at room temperature overnight.
- Example 3 Procedure for the preparation of non-cross-linked chitosan-based films (1% w/V) by acidification with 1% v/v lactic acid
- C_L film Chitosan-based films have been prepared by dissolving 200 mg of chitosan (1% w/V) in 20 mL of an aqueous solution of 1% v/v lactic acid. The solution was maintained under stirring for two hours at 37 °C until complete dissolution of the chitosan. Finally, 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- CS_7030_L film The CS_7030_L films were prepared by dissolving 200 mg of chitosan in 14 mL of aqueous solution acidified with 1% v/v lactic acid.
- CS_3070_L film The CS_3070_L films were prepared by dissolving 200 mg of chitosan in 6 mL of aqueous solution acidified with 1% v/v acetic acid. The solution was maintained under stirring for two hours at 37 °C until complete dissolution of the chitosan. 14 ml of slime was added to the solution and the mixture was kept under stirring for further 10 minutes. Finally, 7.4 mL of mixture were poured into a PE petri dish (5.5 cm diameter): the film was obtained after evaporation of the solvent under laminar hood at room temperature overnight.
- Example 4 Procedure for the preparation of non-cross-linked chitosan-based films (1% w/V) by direct solubilisation in snail slime
- the employed snail slime is acidic, thus suitable for solubilization of chitosan, which needs pH values below 6 to dissolve. It follows that the use of S allows direct solubilization of chitosan through a‘green’ procedure and provides materials where the good characteristics of chitosan are enriched by the peculiar properties of snail slime.
- CS_7030_SOL film The CS_7030_SOL films were prepared by dissolving 200 mg of chitosan in 6 mL of snail slime; the mixture was maintained under stirring for 60 minutes at room temperature; then 14 ml of high purified water was added and the mixture was kept under stirring for further 10 minutes. Finally, 7.4 mL of mixture were poured into a PE petri dish (5.5 cm diameter): the film was obtained after evaporation of the solvent under laminar hood at room temperature overnight.
- CS_3070_SOL film The CS_3070_SOL films were prepared by dissolving 200 mg of chitosan in 14 mL of snail slime; the solution was maintained under stirring for 60 minutes at room temperature; then 6 ml of high purified water was added and the mixture was kept under stirring for further 10 minutes. Finally, 7.4 mL of mixture were poured into a PE petri dish (5.5 cm diameter): the film was obtained after evaporation of the solvent under laminar hood at room temperature overnight. The obtained films are reported in Table 1.
- Example 5 Procedure for the preparation of chitosan-based film cross-linked with 0.1% w/V hyaluronate
- This Example refers to the preparation of cross-linked chitosan films, prepared by acidification with acetic acid or by direct solubilisation in snail slime and subsequent diffusion.
- Crosslinking was performed by diffusion of a solution of sodium hyaluronate (“( 'hitosan hyaluronic acid hybrid film as a novel wound dressing: in vitro and in vivo studies’’ Polym. Adv. Technol.
- hyaluronate is one of the fundamental components of the extracellular matrix of connective tissue. It has also been studied in several biomedical applications for its role in wound healing procedures (stimulates cell proliferation and migration).
- C_A+ H film Chitosan films were initially prepared as described above for the sample C_A in Example 2. The following day 7.4 ml of a 0.1% w/V aqueous solution of sodium hyaluronate (1650 kDa, ACEF spa, Italy) were deposited on the film kept inside the petri dish. The hyaluronate solution gradually diffuses into the chitosan film: the diffusion procedure is completed in about 1 hour, after which the material is left to dry under a laminar hood overnight.
- CS_7030_A+ H film Chitosan films were initially prepared as described above for sample CS_7030_A in Example 2. The following day 7.4 ml of a 0.1% w/V aqueous solution of hyaluronate were deposited on the film kept inside the petri dish. After diffusion, which occurs as described above, of the hyaluronate solution within the film, the material is left to dry under a laminar hood overnight.
- CS_3070_A+ H film Chitosan films were initially prepared as described above for the sample CS_3070_A in Example 2. The following day 7.4 ml of a 0.1% w/V aqueous solution of hyaluronate were deposited on the film kept inside the petri dish. After diffusion of the hyaluronate solution within the film, which occurs as described above, the material is left to dry under a laminar hood overnight.
- CS_3070_SOL+ H film Chitosan films were initially prepared as described above for the sample CS_3070_SOL in Example 4. The following day 7.4 ml of a 0.1% w/V aqueous solution of hyaluronate were deposited on the film kept inside the petri dish. After diffusion, which occurs as described above, of the hyaluronate solution within the film, the material is left to dry under a laminar hood overnight.
- Example 6 Procedure for the preparation of non-cross-linked films based on chitosan (2% w/V)
- C2_A Gly film The C2_A Gly films were prepared by dissolving 400 mg of chitosan (2% w/V) in 20 mL of an aqueous solution of 2% v/v acetic acid. The solution was maintained under stirring for two hours at 37 °C until complete dissolution of the chitosan. Subsequently, 30% w/w glycerol was added (with respect to chitosan weight) and the solution was maintained under stirring for further ten minutes. Finally, 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- C2S_3070_A Gly film The C2S_3070_A Gly films were prepared by dissolving 400 mg of chitosan (2% w/V) in 6 mL of a 2% v/v aqueous acetic acid solution and the solution was kept stirring for two hours at 37 °C until complete dissolution of the chitosan. Subsequently, 14 ml of snail slime and 30% w/w glycerol (with respect to chitosan weight) were added. The mixture was kept under stirring for ten minutes at 37°C, then 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- C2S_7030_A Gly film The C2S_7030_A Gly films were prepared by dissolving 400 mg of chitosan (2% w/V) in 14 mL of a 2% v/v aqueous acetic acid solution and the solution was kept stirring for two hours at 37 °C until complete dissolution of the chitosan. Subsequently, 6 ml of snail slime and 30% w/w glycerol (with respect to chitosan weight) were added. The mixture was kept under stirring for ten minutes at 37°C, then 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- C2S_7030_A films were prepared by dissolving 400 mg of chitosan in 14 mL of aqueous solution acidified with 2% v/v of acetic acid. The solution was maintained under stirring for two hours at 37 °C until complete dissolution of the chitosan. 6 ml of slime was added to the solution and the mixture was kept stirring for further 10 minutes. Finally, 7.4 mL of mixture were poured into a PE petri dish (5.5 cm diameter): the film was obtained after evaporation of the solvent under laminar hood at room temperature overnight.
- C2_L Gly film The C2_L Gly films were prepared by dissolving 400 mg of chitosan (2% w/V) in 20 mL of an aqueous solution of 2% v/v lactic acid. Subsequently, 30% w/w glycerol was added (with respect to chitosan weight). The solution was maintained under stirring for two hours at 37 °C until complete dissolution of the chitosan. Finally, 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- C2S_3070_L Gly film The C2S_3070_L Gly films were prepared by dissolving 400 mg of chitosan (2% w/V) in 6 mL of a 2% v/v aqueous lactic acid solution and the solution was kept under stirring at 37 °C for two hours until complete dissolution of the chitosan. Subsequently, 14 ml of snail slime and 30% w/w glycerol (with respect to chitosan weight) were added. The mixture was left under stirring for ten minutes and finally, 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- C2S_7030_L Gly film The C2S_7030_L Gly films were prepared by dissolving 400 mg of chitosan (2% w/V) in 14 mL of a 2% v/v aqueous lactic acid solution and the solution was kept under stirring at 37 °C for two hours until complete dissolution of the chitosan. Subsequently, 6 ml of snail slime and the 30% w/w glycerol (with respect to chitosan weight) were added. The mixture was left under stirring for ten minutes and finally, 7.4 mL of solution were poured into a PE petri dish (5.5 cm diameter) and allowed to evaporate under a laminar hood at room temperature overnight to obtain the film.
- Example 7 Procedure for the preparation of non-cross-linked films based on gelatine GP and GB films: Gelatine-based films were prepared by placing 1 g of gelatine in 20 mL of high purified water (5% w/V). The solution was maintained under stirring at 38 °C for 30 minutes until the gelatine was completely solubilized. 7.4 mL of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight. Films obtained from swine gelatine are indicated below by the acronym GP, while those obtained from bovine gelatine by the acronym GB.
- GPS_7030 and GBS_7030 films The GPS 7030 and GBS 7030 films were prepared by placing 1 g of gelatine in 14 ml of high purified water. The solution was maintained under stirring at 38 °C for 30 min until the gelatine was completely solubilized, then 6 ml of slime (pure) were added and the mixture was kept under stirring for 5 min without heating. 7.4 mL of this mixture were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- GPS_3070 and GBS_3070 film The GPS 3070, GBS 3070 films were prepared by placing 1 g of gelatine in 6 ml of high purified water. The solution was maintained under stirring at 38 °C for 30 min until the gelatine was completely solubilized: then 14 ml of slime (pure) were added and the mixture was kept under stirring for 5 min without heating. 7.4 mL of this mixture was poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- Example 8 Procedure for the preparation of gelatine-based films cross-linked with citric acid 30% (w/w) with respect to gelatine and addition of glycerol
- Citric acid-incorporated fish gelatine/chitosan composite films’ Food Hydrocolloids 2019; 86: 95-103.
- Citric acid is an additive widely used in both food and medicinal products (e.g. effervescent forms).
- films cross- linked with citric acid maintain the characteristic colour and transparency typical of gelatine (as opposed to materials cross-linked with glurtaraldehyde, or genipine, which become orange and dark blue respectively).
- Citric acid was used for cross-linking in an amount of 30% (w/w) with respect to the gelatine.
- Glycerol was added to the films of the invention as a humectant in order to keep the amount of residual water present in the film constant during storage.
- GP_Gly_CA and GB_Gly_CA films Films were prepared by placing 1 g of gelatine and 300 mg of citric acid (Citric acid, Merck, Germany) in 20 mL of high purified water. The solution was maintained under stirring at the temperature of 38 °C until complete solubilization of the two components, then 30 microlitres of 5M NaOH were added to obtain a pH value of about 7. The mixture was heated to 60 °C and kept at this temperature for 30 minutes, then 300 mg of glycerol were added and the solution kept under stirring for five minutes. 7.4 mL of this mixture were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight. Snail slime can be inserted into these films.
- citric acid Citric acid, Merck, Germany
- GPS_Gly_4060 CA and GBS_Gly_4060 CA films were prepared by placing 1 g of gelatine (either from porcine or bovine origin) and 300 mg of citric acid (Citric acid, Merck, Germany) in 8 mL of high purified water. The solution was maintained under stirring at the temperature of 38 °C until complete solubilization of its two components, then 30 microlitres of 5M NaOH have been added to obtain a pH value of about 7. The mixture was heated to 60 °C and maintained at this temperature for 30 minutes. After such time the mixture was cooled to 37°C under stirring and 12 ml of slime and 300 mg of glycerol were added. The mixture was kept under stirring for 5 minutes, then 7.4 mL of this mixture were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- citric acid Citric acid, Merck, Germany
- GBS_Gly_5050_CA films were prepared by placing 1 g of gelatine and 300 mg of citric acid (Citric acid, Merck, Germany) in 10 mL of high purified water. The solution was kept stirring at the temperature of 38 °C until complete solubilization of its two components, then 30 microlitres of 5M NaOH have been added to obtain a pH value of about 10. The mixture was heated to 60 °C and maintained at this temperature for 30 minutes. After this time the mixture is cooled to 37 °C under stirring after which 10 ml of slime and 300 milligrams of glycerol were added. This amount corresponds to a glycerol mass of 30% (w/w with respect to the amount of gelatine). The mixture was kept under stirring for 5 minutes, then 7.4 mL of this mixture were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- citric acid Citric acid, Merck, Germany
- Example 9 Procedure for the preparation of non-cross-linked hydroxy propyl methyl cellulose-based films 5% w/V
- E5S 7030 and E50S_7030 films The E5S_7030 and E50S_7030 films were prepared by placing 1 g of cellulose in 14 ml of highly purified water. The solution was kept under stirring at room temperature overnight until complete solubilization of the cellulose, then 6 ml of snail slime were added and the mixture was kept under stirring for further 5 minutes. 10.2 grams of this mixture were poured into a PE petri dish (8.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- E5S 3070 and E50S_3070 films The E5S_3070 and E50S_3070 films were prepared by placing 1 g of cellulose in 6 ml of high purified water. The solution was kept under stirring at room temperature overnight until complete solubilization of the cellulose, then 14 ml of snail slime were added and the mixture was kept under stirring for further 5 minutes. 10.2 grams of this mixture were poured into a PE petri dish (8.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- Example 10 Preparation procedure of films containing sodium carboxymethyl cellulose 2% (w/V)
- Preparation of CMC-based films containing snail slime The CMCS 3070 films were prepared by dissolving 0.4 g of CMC into 6 ml of HPW under gentle stirring overnight. Then 14 ml of snail slime were added and the solution maintained under stirring for at least 30 minutes until no bubbles were present.
- Example 11 Preparation procedure of sodium alginate-based films 1% (w/V)
- Alginate (AL) films with different percentages in volume of snail slime were produced (Table 4). In particular, 15, 30 and 50% V/V of S were involved in the preparation of the composite films, adding the relative volume of S to the 1 % w/V solution of AL dissolved at RT in the remaining volume of water.
- AL films were prepared by placing 0.2 g of sodium alginate in 20 mL of HPW (1% w/V). The solution was kept under stirring at room temperature overnight until complete solubilization of the alginate. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature.
- ALS_8515 films were prepared by placing 0.2g of sodium alginate in 17 ml of HPW. The solution was kept under stirring at room temperature overnight until complete solubilization of the polymer, then 3 ml of snail slime were added and the solution was kept under stirring for 30 minutes at room temperature. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature
- ALS_7030 films were prepared by placing 0.2g of sodium alginate in 14 ml of HPW. The solution was kept under stirring at room temperature overnight until complete solubilization of the polymer, then 6 ml of snail slime were added and the solution was kept under stirring for 30 minutes at room temperature. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature
- ALS_5050 films were prepared by placing 0.2g of sodium alginate in 10 ml of HPW. The solution was kept under stirring at room temperature overnight until complete solubilization of the polymer, then 10 ml of snail slime were added and the solution was kept under stirring for 30 minutes at room temperature. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature.
- Example 12 Preparation procedure of sodium hyaluronate (H)-based films 1% (w/V)
- H films were prepared by placing 0.2 g of Hyaluronate in 20 mL of HPW (1% w/V). The solution was kept under stirring at room temperature overnight until complete solubilization of the hyaluronate. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature.
- HS_7030 films were prepared by placing 0.2g of hyaluronate in 14 ml of HPW. The solution was kept under stirring at room temperature overnight until complete solubilization of the hyaluronate, then 6 ml of snail slime were added and the solution was kept under stirring for 30 minutes at room temperature. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature.
- HS_5050 films were prepared by placing 0.2g of hyaluronate in 10 ml of HPW. The solution was kept under stirring at room temperature overnight until complete solubilization of the hyaluronate, then 10 ml of snail slime were added and the solution was kept under stirring for 30 minutes at room temperature. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature.
- HS_100 films were prepared by placing 0.2g of hyaluronate in 20 ml of snail slime. The solution was kept under stirring at room temperature overnight until complete solubilization of the hyaluronate, then 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature.
- HS_7030 Gly films were prepared by placing 0.2g of hyaluronate in 14 ml of HPW. The solution was kept under stirring at room temperature overnight until complete solubilization of the hyaluronate, then 6 ml of snail slime and 30 mg of glycerol were added and the solution was kept under stirring for 30 minutes at room temperature. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room.
- HS_100 Gly films were prepared by placing 0.2g of hyaluronate in 20 ml of snail slime. The solution was kept under stirring at room temperature overnight until complete solubilization of the hyaluronate, then 30 mg of glycerol were added and the solution was kept under stirring for 30 minutes at room temperature. 7.4 ml of this solution were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature.
- Example 13 Preparation procedure of films based on carboxymethyl cellulose and sodium hyaluronate
- the mechanical properties of the films are useful for assessing their suitability for topical application (e.g. cutaneous and mucosal).
- topical application e.g. cutaneous and mucosal.
- uniaxial tensile tests were carried out, fixing the rectangular specimen to two clamps and recording its mechanical behaviour obtaining stress/strain graphs.
- the variation of the following parameters was evaluated: stress at break ( ⁇ 3 ⁇ 4 ), elongation at break (ei,), Young modulus (E) and maximum stress (o m ).
- stress at break ⁇ 3 ⁇ 4
- ei elongation at break
- E Young modulus
- o m maximum stress
- the stress is obtained by dividing the load (applied to the sample, point by point) by the area on which the load acts (such area is obtained by multiplying the width of the specimen by its thickness). It is preferred to use the stress magnitude rather than the load because stress represents a normalized value, and thus allows for a comparison of results from samples of different sizes. In this way, the maximum stress (highest value of the stress-strain curve) and stress at break, which corresponds to the stress recorded at the breaking time of the sample, were evaluated. Depending on the shape of the stress-strain curve (which depends on the characteristics of the tested material) stress at break and maximum stress may coincide or be different.
- the strain represents the elongation of the sample subjected to traction: again, the value is normalized in order to compare samples of different initial lengths. The strain is therefore expressed as the percentage of elongation of the sample with respect to its initial length.
- the elastic modulus (E) represents the tangent to the stress-strain curve in the section of elastic behaviour, then in the first section of the curve for strain values not exceeding 5%. It is a measure of sample stiffness: the higher E is, the greater the stress required to achieve the same strain.
- the parameters examined provide information on the stiffness and fragility of the films.
- low stress at break ( ⁇ 3 ⁇ 4 ), Young modulus (E) and maximum stress (o m ) values and high elongation at break (e b ) are desirable. Indeed, these values indicate high deformability, extensibility, and reduced handling, stiffness and fragility.
- the film thickness was measured by MITUTOYO digital micrometer with a range of 25 mm and a sensitivity of 0.001 mm at six different positions in each specimen.
- the mean thicknesses of 1% w/V chitosan-based films are about 50 pm, while those based on 5% w/V gelatine are about 120 pm.
- the average thicknesses increase, reaching values of about 130 pm for CS 3070 films and 180 pm for GS 3070 films, regardless of the type of gelatine used.
- the thickness of the film is a function of both the content of polymer used and the content of dry matter present in the snail slime (the dry matter is between 3% and 7% w/w, the rest is water). It is important to define the thickness of the film obtained, since other properties of the films depend on this characteristic, such as residual humidity, water vapour permeability and rate of dissolution and release of the active substances.
- the samples were cut into strips 40 mm long and 4 mm wide, the ends of each strip were fixed with the clamps as shown in Figure 2 and the measurement was taken. Measurements were performed using an INSTRON 4465 dynamometer, connected and managed by a SERIES IX software for Windows. The load cell is 1 KN and the crossbar speed was set to 5 mm/min. Stress-strain curves were recorded at a crosshead speed of 5mm/min by the software SERIE IX for Windows. Six measurements were performed for each sample and the results are expressed as mean ⁇ standard deviation and reported in Tables 7, 9 and 10. Mechanical tests were carried out on the samples one day after preparation.
- the materials thus obtained are therefore less fragile than chitosan alone and can be easily stretched by even 100% without breaking exerting a much lower force. This behaviour is very advantageous if the film is to be applied in areas subjected to continuous stresses, such as the groove of the arm or the palm of the hand, for example: in fact, the high deformability of the film and its reduced rigidity mean that the material can accommodate the movements without breaking.
- the prepared materials display both elastic and plastic properties.
- FIG 4(B) are reported, by way of example, the stress-strain curves obtained on the samples GB and GBS 3070.
- the GB sample has a high stress at break (higher than 80 MPa), which also coincides with the maximum stress, low elongation capacity (maximum elongation of about 5%) and a high elastic modulus, as observable from the high slope of the first section of the curve, indicating a high stiffness.
- the GBS 3070 sample has a curve characterised by high elongation (around 70%) corresponding to an extremely low stress at break value (less than 5 MPa). The curve has two sections: a first elastic section, up to deformation values of about 4-5%, followed by a plastic behaviour until breakage.
- the elastic section corresponds to the initial elastic deformation (the material can return to its original shape if the external stress is eliminated, that is, if tension is no longer exerted), while the plastic section is a consequence of the breakage of the interactions that hold the macromolecular chains together, which can thus easily slide on top of each other reaching high deformations at almost constant stresses.
- maximum stress and stress at break do not coincide: the maximum stress is obtained at the end of the elastic section and is proportional to the load that must be applied to break the interchain interactions. The stress at break is measured at the time of breaking and may be lower than the maximum stress.
- the film has a very low elastic modulus (see slope of the line interpolating the first elastic section of the curve), and this indicates that the addition of slime makes the material much less rigid/stiff. Adding slime in such amount substantially changes the mechanical properties of the material, which from rigid becomes plastic.
- Figure 4(C) are reported, by way of example, the stress-deformation curves obtained on the samples E5, E5S_7030 and E5S_3070.
- Sample E5 has a high stress at break (higher than 50 MPa), an elongation of just over 10% and a high elastic modulus, as can be seen from the high slope of the first section of the curve, indicating a high stiffness.
- Addition of slime in large quantities makes the material much less rigid and more easily stretchable. Films in the presence of slime are more deformable and flexible.
- Figure 4(D) reports stress-strain curves obtained from CMC -based films. Films made of CMC are brittle and rigid since they have a high elastic modulus and break at few percent of deformation. Films become more stretchable as a consequence of snail slime addition: in particular, films CMCS 100 show an elastic behaviour and they break at about 60% of deformation.
- the films of the present invention were applied to human skin, nails and lip. Before applying the film, in some cases, the skin was slightly moistened with (drinking) water.
- the film CS 3070 A remains perfectly adhered and is perfectly anatomical even during repeated arm movements, as shown in Figure 5(C). In this case, the film was left adhered for two hours. During this time it showed no signs of detachment.
- Film CS 3070 A was also applied to a nail. Even in such case, the film perfectly adheres to the surface of the nail as it is observable form Figure 5(D), showing a particular of the nail itself.
- the film was adhered to the pig rind using a fixed volume of phosphate buffer pH 7.4 (40 microL), left to adhere for 1 minute.
- the upper plunger, coated with double-sided tape (3M) was lowered until a force of 5 Newton (N) was applied to the film for 30 seconds.
- Cellulose-based films exhibit good adhesive performances on both the substrates. Addition of snail slime enhances the adhesive properties of the films and the effect is more evident when the polymer is dissolved into the highest extract content.
- Solubility evaluation is of particular relevance in order to understand the films stability in aqueous solutions and thus to identify a specific film application.
- the films were cut into squares of an area equal to 2.25 cm 2 and dried at 37 ° C, for a day. After that, they were weighted and immersed in 5 mL of HPW. After 24 hours the samples not completely dissolved were removed from water, and dried again at 37 ° C until a constant weight was obtained. Samples CMCS 100 and CMCS 3070 do not dissolve for more than two weeks while CS_8515_A, C2S_7030_A, C2S_7030_AGly do not dissolve for more than two months.
- HPMC -based films (Table 3) containing or not snail slime immediately solubilize when added to water, whatever their composition.
- CMC films While pristine films solubilize in few minutes, compositions CMCS 3070 and CMCS 100 are able to preserve their structure for more than one week. In fact, after 24 hours the solubility was 45% and 60%, respectively, and these values remain approximately constant even after 7 days.
- Solubility% — . - . , f - : - :— X 100
- ALS 7030 and ALS 5050 are water insoluble cross-linked films.
- PB phosphate buffer
- the degree of swelling of the films indicates the capacity of the film to absorb water when placed in contact with the wet skin or in the aqueous environment that wets the mucous membranes and the extent of this swelling can modify the time necessary to promote adhesion, the mechanical properties of the films and finally the time of dissolution or release of a drug.
- the degree of swelling affects the drug release, so depending on the desired release rate, it is possible to modulate the swelling of the material.
- measuring the degree of swelling allows having information on the degree of cross-linking of the material: as a matter of fact, the higher the cross-linking of a film, the lower the capacity of the film to absorb water.
- the swelling degree is therefore strongly influenced by the composition of the films, in particular by the type of hydrophilic polymer (presence of hydroxyl groups, amines and type of final chain), concentration of slime rich in mucopolysaccharides and other additives such as humectants and plasticisers.
- dry sample weight means the weight of the air-dried film before being immersed in PB and wet sample means the weight of the sample after each time of immersion in PB (times specified above).
- the GB films reach a swelling degree of 1000% after 4 h;
- the films of GBS_3070 type reach the maximum swelling degree (500%) after 30 minutes, after which they begin to solubilise;
- the GP films reach a swelling degree of 800% after 4 h;
- the films of the GPS 3070 type also reach a swelling degree of 800% after 4 h.
- Non-crossed-linked gelatine both bovine and porcine, is a highly hydrophilic material, capable of absorbing large amounts of PB.
- swine gelatine absorbs less water than bovine gelatine.
- the result should not be surprising, because the amount of water absorbed depends on several factors, including the Bloom index, which is a measure of the strength of the gel obtained under certain conditions and which in turn depends on the degree of renaturation that the protein can achieve when, after being solubilised in water, it is allowed to congeal.
- the degree of renaturation indicates the amount of formation of protein moieties in which the triple-helix structure is restored.
- Such moieties are stabilized predominantly by H bonds and interactions between polar groups: such interactions are the same as those that preside over the absorption of water molecules so that, due to the lack of polar groups available for absorption, the degree of swelling decreases. Since the Bloom index of the bovine gelatine is always lower than that of pig gelatine, the degree of renaturation of pig gelatine will be higher, resulting in a lower ability to absorb water.
- the GBS 3070 film is more soluble: in fact, after 30 minutes the sample weight tends to decrease, a clear indication that it is solubilizing.
- the explanation may lie in the different isoelectric point presented by the protein obtained from swine and from bovine: this involves interactions of different magnitudes with the slime, which, having a very acidic pH (2.5-3), certainly has positive charges.
- non-cross-linked chitosan-based films can be proposed for example for the topical treatment of cellulite imperfections.
- One of the advantages lies in the fact that the film, after being applied and having exerted its action, can be removed by simple cleaning with warm water. The product is completely natural and therefore does not pollute.
- Insoluble films made of chitosan and snail slime show a degree of swelling which is about 150% for both the formulations not containing glycerol and 50% for the sample C2S_7030_A Gly after 24h of immersion in phosphate buffered solution.
- CMCS-3070 and CMCS 100 which are insoluble. Both the samples reach a degree of swelling of 100% after 24 hours, then the value does not change over time.
- the snail slime was freeze-dried as such and in addition to a lyoprotectant (dextran at 2 % w/w).
- Example 20 Production and mechanical properties of films obtained with the freeze dried snail slime
- Gelatine film using lyophilised snail slime (lyophilised in presence of 2 % w/w of dextran) were prepared with two different amounts of lyophilisate.
- the GBS_3070_FDS films were prepared by placing 1 g of gelatine in 6 ml high purified water, the solution was maintained under stirring at 38 °C for 30 minutes until complete solubilization of the gelatine; the lyophilisate obtained from 14 mL of snail slime was re- suspended in the same volume of high purified water and finally added to the gelatine solution. The mixture was maintained under stirring for 5 min without heating. 7.4 mL of this mixture were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- the GBS_7030_FDS films were prepared by placing 1 g of gelatine in 14 ml of high purified water, the solution was kept under stirring at 38 °C for 30 minutes until complete solubilization of the gelatine; the lyophilisate obtained from 6 mL of snail slime was re suspended in the same volume of high purified water and finally added to the gelatine solution. The mixture was maintained under stirring for 5 min without heating. 7.4 mL of this mixture were poured into a PE petri dish (5.5 cm diameter): the film is obtained by solvent evaporation under a laminar hood at room temperature overnight.
- the films thus obtained show a similar appearance to that obtained by using the pure (liquid) snail slime.
- Mechanical tests were conducted for the GBS 3070 FDS film. Stress at break c 3 ⁇ 4 (MPa), elongation at break percentage 8 b (%), elastic modulus E (MPa) and maximum stress o m (MPa) were measured according to the methods reported in Example 14. The obtained values are compared (Table 13) with the gelatine-only film.
- Procedure 1 The C_A, CS 3070 A and CS 7030 SOL films were solubilized in 2 mL of sterile water then filtered (filters with 0.2 nm pores). The samples were then subjected to cell proliferation assay by CCK8 colorimetric test (Cell Counting Kit-8 Dojindo Molecular Technologies, Rockville, MD, EISA). Monkey kidney epithelial cells (VERO, ATCC CCL- 81) were used for the test.
- VERO cells 24 hours prior to the experiment, were transferred to a 96-well flat bottom plate at the density of 10 4 cells/100 pL of culture medium (Eagle's Essential Medium with addition of 1% Levoglutamine, 1% Streptopenicillin, 10% fetal bovine serum from Thermo Fisher Scientific US). The plate was incubated at 37 °C and 5% CO2. The exhausted medium was removed after 24 hours and the cellular monolayer washed with PBS (saline phosphate buffer). The cells were then incubated with 100 pL medium containing scalar dilutions (1 :2) of solubilized samples (starting at 1 : 10 dilution).
- culture medium Eagle's Essential Medium with addition of 1% Levoglutamine, 1% Streptopenicillin, 10% fetal bovine serum from Thermo Fisher Scientific US.
- PBS saline phosphate buffer
- MEM Eagle's Minimal Essential Medium
- cells were seeded into 96-well plates at 10 4 cells/well, and incubated at 37 °C for 24 h; subsequently, cell monolayer was washed with PBS and incubated with 100 pL of the different solutions, previously diluted twenty times in cell culture medium. Then, cell viability was assessed by aWST8-based assay according to the manufacturer's instructions (CCK-8, Cell Counting Kit-8, Dojindo Molecular Technologies, Rockville, MD, USA). After 72 h of incubation, cell monolayer was washed with PBS, and 100 pL of fresh medium containing 10 pL of CCK-8 solution were added. After 2 h at 37 °C, the absorbance was measured at 450/630nm; results were expressed as the percentage of absorbance relative to the untreated controls. Experiment was carried out in triplicate.
- C L and C_A films did not interfere with Vero cells metabolism after 72 h of incubation (93.7% and 103.3%, respectively, and relative to untreated control cells) (Fig. 10).
- Addition of snail slime to these films induced an improvement in cell viability, especially for the samples of CA series.
- These samples exhibit a dose dependent increase in Vero viability as function of S content.
- the lowest cell viability was detected for C SOL films (72.7%); nevertheless, as a material is considered cytotoxic when its viability is ⁇ 70% in comparison to untreated controls [UNI EN, ISO 10993-5, Biological Evaluation of MEDICAL DEVICES Part 5: Tests for in Vitro Cytotoxicity, 2009], all samples displayed a promising safety profile.
- Human normal skin fibroblast BJ-5ta (ATCC, VA, USA, lot 63229591) were cultured in a 4: 1 (V/V) mixture of Dulbecco’s Modified Eagle’s Medium and Medium 199, supplemented with 10% FCS and 0.01 mg/ml hygromycin B.
- BJ-5ta cells were plated at a density of lxlO 4 cells/cm 2 in 24-well plates containing the 2% w/V chitosan-based films (C2S_7030_A). Cells were also plated in wells for negative (CTR-, DMEM only) and positive (CTR+, DMEM + 0.05% phenol solution) controls.
- Plates were cultured in standard conditions, at 37 ⁇ 0.5°C with 95% humidity and 5% ⁇ 0.2 CO2 up to 72 hours.
- Cell viability was measured at 24 and 72 hours by Alamar Blue reagent (Cell Viability Reagent, LIFE Technologies Corp., Oregon, USA), added (1: 10 v/v) to each well and incubated for further 4 hours at 37°C.
- a redox indicator changes its color in response to the chemical reduction of the medium resulting from living cells. The results are expressed as relative fluorescence units (RFU).
- LDH Lactate Dehydrogenase
- FGF Fibroblast Growth Factor
- COL1 Collagen type 1
- the FGF and the COL1 immunoenzymatic tests were performed following manufacturer’s instruction and absorbance was spectrophotometrically measured at 450 nm. The measured absorbance values were converted into FGF (pg/ml) and COL1 (ng/ml) by means of a calibration curve obtained from standard solutions.
- Fibroblasts play an important role in wound healing, synthesizing collagen, one of the main components of the extracellular matrix.
- FGF promotes cell proliferation, angiogenesis and endothelial cell migration, contributing to improve wound healing.
- the film significantly stimulated FGF (Fig. 11(C)) and COL1 (Fig. 11(D)) synthesis in comparison with CTR-.
- COL1 reached significant higher value when compared to CTR-, while it was not detected in CTR+ group.
- the WVTR Water Vapour Transmission Rate, g/hm 2
- the WVTR Water Vapour Transmission Rate, g/hm 2
- This measurement is performed as described in the article“Preparation and characterization of active gelatine-based films incorporated with natural antioxidants”, Jian-Hua Li et al., Food Hydrocolloids 37 (2014) 166-173.
- Appropriately sized glass vials containing 3g anhydrous calcium chloride (relative humidity (RH) 0) are used. Silicone is placed on the mouth of the vial onto which the film being measured is adhered.
- the vials after having been weighed, are placed inside a desiccator saturated with 50% relative humidity by saturated NaCl solution.
- the desiccator is placed at 30 °C: the vials are weighed every day for 12 days.
- a linear trend is obtained: the interpolation of the graph provides the parameters of the line.
- the value of WVTR was calculated from the slope of the straight line divided by the surface of the tested film (for exemplary films of the invention, this value corresponds to 0.00013m 2 ):
- G/t slope of the line (expressed in g/h)
- A sample area in m 2 (equal to 0.00013m 2 ).
- the water vapour permeability is the water vapour transmission rate through a flat film area induced by a vapor pressure between two surfaces under specific conditions of moisture and temperature or the ease of moisture for penetrating and passing through the hydrophilic portion of film (E. Hernandez, Edible coatings for lipids and resins, in: J.M. Krochta, E.A. Baldwin, M.O. Nisperos-Carriedo (Eds.), Edible Coatings and Films to Improve Food Quality, Technomic Pub Co, Lancaster Pa 1994, pp. 279-304.).
- the WVP value is calculated with the following formula:
- Dr corresponds to the vapour tension of a saturated solution of [Mg(N0 3 ) 2 ] at 25 °C equal to 1670 Pa (table value).
- Table 14 reports the WVP values obtained from Equation reported above.
- the presence of snail slime into films composition strongly modifies the Water Vapor Permeability. Values decrease by one or two orders of magnitude as a function of S content.
- the WVP values vary from 1.3-10 10 to 6.5 ⁇ 10 12 g m/s m 2 Pa when measured on E5 and E5S_100, respectively.
- the antibacterial activity of the cellulose-based films was assessed in vitro by means of a standardized Kirby-Bauer (KB) diffusion test on Mueller-Hinton agar plate [EUCAST: The European Committee on Antimicrobial Susceptibility Testing, Breakpoint Tables for Interpretation of MIC s and Zone Diameters, Version 6.0, 2016. http://www.eucast.org] against both Gram positive and Gram negative bacteria.
- the following panel of Gram positive and Gram negative reference bacterial strains was selected: Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), Enterococcus faecalis (ATCC 29212), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), and Klebsiella pneumoniae (ATCC 9591).
- disks containing gentamicin were used as controls [CLSI, 2016Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement, CLSIdocument M100-S25 (2015)]. All experiments were performed in duplicate and in different days.
- Tables 15 and 16 report the mean diameter of the bacterial -free zone measured for each composition on Gram-Positive and Gram-Negative bacterial strains, respectively. All the films made only of cellulose did not show any antibacterial activity, while a halo around the disk-shaped samples appeared when the composition is enriched by a snail slime addition, clearly indicating its antibacterial effect.
- Table 15 mean diameters of the inhibition zones for Gram-positive bacteria cultured on
- Table 16 mean diameters of the inhibition zones for Gram -negative bacteria cultured on
- the cellulose-based disks containing S at 30% displayed inhibitory zone for Pseudomonas aeruginosa, an opportunistic pathogen recognized as an important cause of cutaneous, corneal, and respiratory tract infections.
- the in vitro antibacterial activity of the chitosan-based films was evaluated against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC25922) selected as controls and representative strains for Gram-positive and Gram-negative bacteria.
- Results are reported in Table 17. There was no difference between the antibacterial effects on the different microbial species.
- Example 25 Sunscreen properties Barrier properties of the films against UV-Vis light were investigated by means of Cary 60 Uv-Vis spectrophotometer: spectra were acquired in transmittance mode in the UV-Visible range (from 200 to 800 nm) on films cut into 1 cm wide rectangular strips directly inserted into the sample holder. Transparency was evaluated by the following equation:
- Uoo is the transmittance at 600 nm and X is the thickness of the film (pm) measured as described above.
- LAE laauroyl arginate ethyl
- films for food packaging ideally preserve/protect food from sunbeams, especially from UV radiation, which has sufficient energy to alter food.
- the in vitro antimicrobial activity of drug-loaded gelatin films was evaluated against Candida albicans (ATCC 10231) and clinical isolates (F. Bonvicini et ah, Molecules , 2019, 24, 372): C. albicans C. glabrata, C. parapsilosis, C. tropicalis and C. krusei, selected since they represent the main systemic fungal infections.
- TGA was carried out using a Perkin-Elmer TGA-7. Heating was performed in a platinum crucible in air flow (20 mL/min) at a rate of 10 °C/min up to 800 °C. Samples weights were in the range of 5-10 mg.
- Fig. 16 films obtained in acetic acid (C_A) show two prominent reflections at about 9.2° and 12 20, together with a sharp peak at 19720 attributed to type II hydrated polymorph of chitosan acetate [W. Chang, et ak, Food Hydrocoil. 90 (2019) 50-61.].
- Snail slime is a complex mixture of active ingredients and it is not easy to discriminate the effectiveness and the interaction of each component with the chitosan functionalities.
- the comparison of the patterns collected from snail slime-containing samples puts into evidence that the material becomes less crystalline on increasing the S content.
- CS 7030 A films show only two broad halos, centered at about 8° and 20° of 2Q, while only a broad halo centered at 20° of 2Q can be detected when the samples contain a greater amount of solution (CS 7030 A).
- the infrared absorption spectrum of C_A films displays a number of bands which can be ascribed to the hydrated polymorph of chitosan [C. Qiao, et ak, Carbohydr. Polym. 206 (2019) 602-608]
- the absorption band at about 1640 cm -1 can be assigned to the C O stretching (amide I), whereas those centered at about 1540 and 1390 cm -1 can be attributed to NWH bending (amide II) and CWN stretching, respectively [I. Laceta, et al., Carbohydr. Polym.
- C_A films display three steps of thermo-oxidative degradation [M. Lavorgna, et al., Carbohydr. Polym. 82 (2010) 291-298] The first one, in the temperature range 35- 160 °C, is attributed to the loss of absorbed water. The second one, between 160 °C and 460 °C and centered around 310 °C, corresponds to the chemical degradation and deacetylation of chitosan [S.F.Wang, et al. Polym. Degrad. Stab.
- thermogravimetric plot of C L differs from that of C_A in the first region, which shows two distinct weight losses in the range 37-240 °C, in agreement with the different structures evidenced by XRD and FT- IR data.
- the derivative plot of TGA (DTG) of freeze-dried S (Fig. 17) displays a weight loss centered at 190 °C, which accounts for about 70% wt. of weight loss, and further degradation steps between 300 and 800 °C, probably due to the degradation of residues.
- thermogravimetric plot is shown by C SOL, with just some shift of the degradation steps to higher temperatures.
- Water addition causes just a reduction of the relative amount of the first weight loss.
- S is added to the composition of C_A and C L, all the films display similar thermogravimetric plots to that of C SOL series: in particular, the thermal degradation starts at a temperature lower than that of pure chitosan films and the first mass loss, determined between 37 °C and 300 °C, accounts for about 35% wt. and 48% wt. for the 7030 and 3070 compositions, respectively. Moreover, no water loss was observed between 35 °C and 160 °C.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT201900004940 | 2019-04-02 | ||
| PCT/EP2020/059427 WO2020201439A1 (en) | 2019-04-02 | 2020-04-02 | Polymer films comprising material secreted by gastropods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3946281A1 true EP3946281A1 (en) | 2022-02-09 |
Family
ID=67108077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20714636.6A Pending EP3946281A1 (en) | 2019-04-02 | 2020-04-02 | Polymer films comprising material secreted by gastropods |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3946281A1 (en) |
| WO (1) | WO2020201439A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116194073A (en) | 2020-07-21 | 2023-05-30 | 化美有限责任公司 | Diester cosmetic preparations and uses thereof |
| CN114699563B (en) * | 2022-02-22 | 2024-02-02 | 中国医科大学附属盛京医院 | Supported polyether polyurethane film, preparation method and application thereof |
| EP4316535B1 (en) | 2022-08-02 | 2024-11-20 | Marija Glavash Dodov | Wound healing composition containing snail mucus |
| CN117959372B (en) * | 2024-04-01 | 2024-06-21 | 北京合源汇丰医药科技有限公司 | Therapeutic pharmaceutical composition for peptic gastric ulcer and preparation method thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69221686T2 (en) | 1991-03-01 | 1998-04-02 | Atherton Investments Ltd | THERAPEUTIC AND COSMETIC COMPOSITIONS FOR SKIN TREATMENT |
| US20100233111A1 (en) | 2008-04-06 | 2010-09-16 | William Wang | Gastropod biological fluid, method of making and refining and use |
| CL2011000143A1 (en) | 2011-01-21 | 2012-01-06 | Muciderm S A | Pharmaceutical composition comprising snail drool helix aspersa müller dissolved in a base of body cream, natural extract of calendula and propolis or almond oil; procedure for obtaining the composition; and its use to prepare a medicament or device useful for preventing or treating ulcer-like conditions or wounds, such as ulcers or diabetic foot wounds. |
| ITFE20110011A1 (en) | 2011-07-21 | 2011-10-20 | Michele Borghi | METHOD AND CONGEGNO FOR THE EXTRACTION OF BAVA DI LUMACA |
| CL2014002248A1 (en) | 2014-08-25 | 2014-10-17 | Muciderm S A | Pharmaceutical composition comprising snail drool helix aspersa müller (5% to 50%), chamomile extract (5% to 10%) and honey (5% to 10%); preparation procedure; use of the composition because it serves to prepare a medicament or device useful for preventing or treating lesions derived from psoriasis. |
| CL2014002729A1 (en) | 2014-10-10 | 2014-12-19 | Muciderm S A | Pharmaceutical composition consisting of snail drool helix aspersa müller (20-50%), chamomile extract (1-4%), propolis (1-4%) and additives and / or excipients, with a viscosity of 10 to 1000 pa- s, in the form of lotion, cream, soap or gel; procedure to obtain it; and its use to prevent or treat pathologies of rosacea. |
| TWI728957B (en) | 2014-10-31 | 2021-06-01 | 美商盧伯利索先進材料有限公司 | Thermoplastic polyurethane film for delivery of active agents to skin surfaces and use and forming method thereof |
| CN107050048B (en) * | 2017-05-12 | 2020-05-12 | 浙江崇山生物制品有限公司 | Cold compress patch and preparation method thereof |
-
2020
- 2020-04-02 EP EP20714636.6A patent/EP3946281A1/en active Pending
- 2020-04-02 WO PCT/EP2020/059427 patent/WO2020201439A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020201439A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6869974B2 (en) | Petrolatum-based delivery system for active ingredients | |
| Echazú et al. | Development and evaluation of thymol-chitosan hydrogels with antimicrobial-antioxidant activity for oral local delivery | |
| WO2020201439A1 (en) | Polymer films comprising material secreted by gastropods | |
| JP6069394B2 (en) | Pharmaceutical composition | |
| EP3017808B1 (en) | Water-soluble hyaluronic acid gel and method for producing same | |
| JP2763492B2 (en) | Ointment for wound treatment | |
| CN107185031B (en) | A kind of biologically active medical dressing and preparation method thereof | |
| CN116099035B (en) | Composite antibacterial hydrogel dressing and preparation method and application thereof | |
| Di Filippo et al. | Novel drug-loaded film forming patch based on gelatin and snail slime | |
| CN102427802A (en) | Medicinal cream prepared by using silver sulfadiazine and chitosan and preparation method thereof | |
| JP2025061046A (en) | Liquid Compositions Comprising Chitosan for Influencing the Skin Microbiota of a Subject - Patent application | |
| Arpa et al. | Novel benzydamine hydrochloride and chlorhexidine gluconate loaded bioadhesive films for local treatment of buccal infections | |
| CN104740141B (en) | A kind of antimicrobial spray and preparation method thereof | |
| CA3079544A1 (en) | Topical composition for improved healing of open wounds | |
| US20230381217A1 (en) | Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease | |
| JP7593977B2 (en) | Collagen hydrogel film forming agent | |
| EP3572100B1 (en) | Composition for stimulating epithelial cell growth | |
| CN111012944A (en) | Liquid dressing based on alginate and hyaluronic acid and preparation method thereof | |
| EP3656404A1 (en) | Film for topical use for treating skin lesions and method for producing and applying same | |
| RU2799938C1 (en) | Liquid hydrogel patch and methods of its production | |
| Wang et al. | Alginate/Gelatin Sponges Composited with ZnO Sponge Effective Extensibility and Compressibility as a Wound Dressing for the Care of Fracture Surgery | |
| LV13959B (en) | Adenylate deaminase containing hidrogel and use thereof for the treatment of dermal wounds (ulcers) | |
| CN116688221A (en) | Skin wound repairing dressing and preparation method thereof, and skin wound repairing film | |
| bin Bai | Honey gel and film for burn wound | |
| Hatem | Preparation and Evaluation of Curcuma Longa Loaded Chitosangelatin Composite Films for Wound Healing Activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20211022 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20220720 |